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Abstract 26 
The specific niche adaptations that facilitate primary disease and Acute Lymphoblastic 27 
Leukaemia (ALL) survival after induction chemotherapy remain unclear. Here, we show that 28 
Bone Marrow (BM) adipocytes dynamically evolve during ALL pathogenesis and therapy, 29 
transitioning from cellular depletion in the primary leukaemia niche to a fully reconstituted 30 
state upon remission induction. Functionally, adipocyte niches elicit a fate switch in ALL cells 31 
towards slow-proliferation and cellular quiescence, highlighting the critical contribution of the 32 
adipocyte dynamic to disease establishment and chemotherapy resistance. Mechanistically, 33 
adipocyte niche interaction targets posttranscriptional networks and suppresses protein 34 
biosynthesis in ALL cells. Treatment with general control nonderepressible 2 35 
inhibitor (GCN2ib) alleviates adipocyte-mediated translational repression and rescues ALL 36 
cell quiescence thereby significantly reducing the cytoprotective effect of adipocytes against 37 
chemotherapy and other extrinsic stressors. These data establish how adipocyte driven 38 
restrictions of the ALL proteome benefit ALL tumours, preventing their elimination, and 39 
suggest ways to manipulate adipocyte-mediated ALL resistance. 40 




Despite remarkable improvements in the treatment of paediatric ALL with cure attainable for 43 
the majority (>80%) of patients1, more than half of adults with ALL will relapse and die within 44 
5 years of diagnosis despite achieving an excellent initial response to treatment 2. These 45 
results indicate, that whilst current treatments are effective at eradicating the bulk of the 46 
adult ALL tumour, complete disease eradication in these patients is rare and individuals 47 
remain at risk of disease recurrence. Thus, a central quest in adult ALL is to define the 48 
critical drivers of leukaemia cell persistence as a key strategy for overcoming eventual 49 
therapy failure. Clinically, the therapy-surviving leukaemia, is characterised as the minimal 50 
residual disease (MRD), which strongly and independently predicts a high subsequent risk of 51 
disease recurrence 3-5, emphasizing the key importance of these targets to ALL evolution. 52 
Hallmarks of therapy-latent MRD subclones include intrinsic chemoresistance, dormancy 53 
and long-term persistence as well as functional plasticity, as assessed experimentally 6,7 and 54 
predicted clinically. However, the regulatory mechanisms underpinning these aberrant states 55 
are not completely understood. Of relevance here is the increasing understanding of the 56 
broad biological context of MRD subclone escape beyond that predicted by genotype and 57 
epigenetics alone 8,9, raising interest in nongenetic drivers of this process 10. The relevant 58 
player here is the bone marrow microenvironment (BMM), the primary residence of ALL;  59 
comprising a  highly diverse network of cellular (mesenchymal stroma, osteoblasts and 60 
endothelial cells), soluble and structural factors that work together to coordinate and 61 
maintain haematopoietic stem cell (HSC) function 11. To perform its role, the BMM must 62 
adapt to changing physiological contexts while still regulating and maintaining HSCs, 63 
emphasizing the principle that BMMs are inherently dynamic 12. This distinct property of the 64 
BM niche is co-opted by leukaemia cells to support developing tumours and to shaping the 65 
ecological competition between leukaemia and healthy haematopoiesis, a process driven by 66 
aberrant crosstalk between leukaemia cells and BM stroma 13-17. Upon exposure to 67 
chemotherapeutic stress, BMMs undergo further adaptation12,18,19, highlighting the 68 
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continuously evolving habitat in which leukaemia cells reside. These findings indicate that 69 
niches in the BMM may differ dynamically during primary disease and after chemotherapy 70 
treatment 18,19. However, many studies fail to account for these niche dynamics explicitly and 71 
from the outset. Moreover, the appropriate context for MRD (<5% leukaemia blasts) is 72 
defined after the transition to morphological remission, yet the niche in this setting has yet to 73 
be fully defined. Where this paradigm has been applied, emergent and novel mechanisms of 74 
niche-resistance have been identified 14,20, highlighting the fundamental importance of 75 
temporal dynamics in determining which events precipitate treatment failure. 76 
We therefore hypothesized that the evolving course of BM niches from ALL disease through 77 
to remission-inducing chemotherapy would provide a tool for mapping dynamic parameters 78 
that temporally and biologically contribute to subclone-specific resistance. Here we show, 79 
that the transition from disease to treatment and remission rebuilds the adipocytic BM niche, 80 
a major BMM implicated in ALL resistance, and demonstrate a previously unknown capacity 81 
of adipocytes to non-cell autonomously repress the ALL proteome as a mechanism for 82 
increasing ALL cell quiescence and multistress resistance that may ultimately contribute to 83 
leukaemia re-evolution.  84 
 85 
Results 86 
The adipocyte BM niche is dynamically remodelled during ALL pathogenesis and 87 
treatment 88 
To probe the transitional nature of BMM, we compared the composition of matched BM 89 
biopsies taken at initial ALL diagnosis and after remission induction by gross histology in 90 
eight adult ALL patients. Our studies were limited to B lineage ALL (B-ALL), which accounts 91 
for >80% of the disease incidence 21. Consistent with the assertion of niche evolution, we 92 
observed profound remodelling of the BMM accompanying ALL development and again after 93 
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therapeutic intervention, most strikingly affecting adipocyte compartments, which were 94 
profoundly depleted in ALL-BMs compared to healthy controls, with apparent adipocyte 95 
reconstitution upon remission attainment (Fig. 1a). Adipocytes are microenvironmental cell 96 
types that have established roles in ALL resistance, 14,17,19,22 23-27, however the niche 97 
dynamics leading to this stage have been minimally explored, prompting us to investigate 98 
these BM components further. We first applied custom image analysis to quantify these 99 
macroscopic changes, further revealing both a loss of adipocyte numbers (Fig. 1b) and 100 
major reductions in adipocyte size (Fig. 1c) at ALL diagnosis, implicating both of these 101 
factors in the profound adipocyte suppression observed under this condition. In contrast, 102 
remission biopsies demonstrated an evolution to normal adipocyte numbers (Fig. 1b), 103 
indicating that remission states reset adipocyte population homeostasis. These outcomes 104 
differ from those reported in AML, where chemotherapy leads to an inhibition of 105 
adipogenesis in the BM 28.  Notably, remission states did not fully normalize adipocyte size 106 
(Fig.1d and Table S1a), suggesting that BM adipocyte numbers in particular display striking 107 
sensitivity to the presence of ALL. Importantly, ALL-associated adipocyte suppression was 108 
unrelated to BM cellularity, confirming that these changes reflected absolute versus 109 
proportional losses. (Supplementary Fig. S1a and S1b). We additionally measured 110 
adiponectin production in the marrow plasma from ALL patients as a functional marker of BM 111 
adiposity 29, and showed it was reproducibly decreased (Fig.  1e), consistent with the 112 
population-level losses observed histologically. Altogether, these data clarify that the BM 113 
adipocyte stroma is not a prominent component of the primary tumour microenvironment but 114 
the emergent niche associated with the remission response. 115 
To investigate how these niche dynamics relate to clinical chemoresistance, we examined 116 
ALL cell interactions in BM trephines from patients who failed to achieve complete remission 117 
(>5% blasts morphologically after induction therapy). These analyses revealed two 118 
consistent patterns across independent BM biopsies; chemoresistant ALL cells were 119 
distributed either interstitially throughout the marrow (Fig. 1f) or in close neighbouring 120 
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proximity to adipocytes. Thus, while chemoresistance is spatially heterogeneous within the 121 
BM niche, as previously suggested 17, distinct physical interactions with the surrounding 122 
adipocyte stroma are recurring features of drug survival in ALL. 123 
 124 
ALL corrupts the functioning and lineage priming of the adipocyte precursor 125 
mesenchymal stromal cell (MSC) population 126 
To investigate the mechanism by which adipocytes are depleted in ALL-BMMs, we 127 
performed a global evaluation of the BM-MSC axis, hypothesizing that these precursors for 128 
BM adipocyte generation were disrupted by ALL disease. We found that MSCs could be 129 
generated with similar success from ALL vs healthy control BM (Table Supplementary 2a) 130 
and that the BM-MSC phenotype was highly conserved in ALL disease (Supplementary 131 
Fig. 2a), 30 confirming these were bona fide MSC isolates. We further assessed the growth 132 
properties of ALL-MSCs using the growth rate in vitro as a measure of proliferative potential 133 
and where cell numbers permitted functional assessment of clonogenic capacity. We 134 
observed a nonuniform growth response in ALL-MSCs, reflecting expected differences in 135 
tumour and host biology. We therefore dichotomized growth data into high and low 136 
performers defined by the mean number of ALL-MSCs (Fig. 2a). High performers constituted 137 
a small subgroup (3/12, 25%) whose growth activity and CFU-F were indistinguishable from 138 
healthy BM-MSCs; however, most ALL-MSCs (9/12, 75%) demonstrated significantly 139 
reduced growth capacity (mean ± SEM: ALL-MSCs 0.095 ± 0.046 vs healthy-MSCs 0.254 ± 140 
0.041), although interestingly, they retained CFU-F forming potential (Fig. 2b), suggesting 141 
that the low expansion capacities of ALL-MSCs are driven principally by defective colony 142 
growth vs colony formation. We next assessed the multidifferentiation potential of ALL-MSCs 143 
following in vitro developmental induction. Unexpectedly, we found that ALL-MSCs had a 144 
significantly enhanced capacity for adipogenic differentiation (2.87 ± 0.29-fold increase; n=7; 145 
***p=0.0003), as determined by cell staining for adipocyte-specific fatty acid binding 4 146 
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(FABP4) (Fig. 2c), without any reciprocal disturbance in osteogenesis (Fig. 2d), indicating 147 
that ALL pathogenesis significantly affects the lineage priming of MSCs in an adipocyte-148 
biased manner. As the adipogenic potential of BM-MSCs in AML disease and similar 149 
conditions has been shown to decrease31,32, although not in all reports33, this raises the 150 
possibility that altered differentiation fates in ALL-MSCs may represent a tumour-specific 151 
interplay.  152 
To test the possibility that ALL cells may directly induce changes in their surrounding stromal 153 
cells, we tested the effect of leukaemic serum on healthy age matched MSC stroma (Fig. 154 
2e). We found that enhanced adipocyte commitment could be reproduced by exposing 155 
healthy MSCs to leukaemic but not HSC-enriched GCSF-mobilized peripheral blood 156 
(GMPB)-conditioned media, confirming a direct role of leukaemia specific factors in altering 157 
the cell fate determination of mesenchymal stroma. 158 
To gain further insight into the transcriptional programmes underlying the altered 159 
functionality and commitment of ALL-MSCs, we performed RNAseq studies on MSCs from 160 
three healthy and three low performer ALL-BMs (ALL12, ALL13, ALL22) at the P4 expansion 161 
stage. Three-dimensional principal component visualization clearly differentiated ALL-MSCs 162 
from their healthy counterparts based on log2 transformed unsupervised global profiles 163 
suggestive of disease-specific transcriptional modulation (Fig. 2f). Further gene set 164 
enrichment analysis (GSEA) of these global RNA-seq datasets identified genes involved in 165 
cellular metabolism and multiple aspects of cell cycle function (Fig. 2g and 2h) as 166 
preferentially downregulated in ALL-MSCs, whereas no gene sets were identified as 167 
significantly (FDR q-value<0.05) upregulated. Notably, the BURTON_ADIPOGENESIS 168 
KEGG pathway, which specifies a committed gene program for adipocyte differentiation, was 169 
not significantly enriched in the ALL-MSCs, confirming i) that ALL-MSC isolates were not 170 
adipocyte precursor cells and ii) that ALL-MSCs are poised rather than committed to 171 
programmed adipocyte differentiation. To validate the findings of GSEA suggesting 172 
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attenuated cell cycle function in ALL-MSCs, we performed a functional analysis in four low-173 
performer ALL-MSCs (ALL12-14, ALL22) at the P4 expansion stage. This analysis confirmed 174 
that ALL-MSCs display slower proliferation kinetics (Fig. 2h), providing a potential 175 
mechanistic basis for their impaired growth function in vitro. 176 
Collectively, our data suggest that ALL disease corrupts regenerative growth and the 177 
differentiation of MSCs. Such perturbations may lead to a reduced number of MSC 178 
precursors inhabiting the BM of ALL, which may account for disease-associated loss of 179 
adipocyte stroma. However, accumulation of adipocyte-primed MSCs, in the context of 180 
adipocyte-depleted ALL-BM, leads to the proposal that their differentiation must be stalled, 181 
most likely through a blast-specific mechanism, an effect that likely is reversed upon ALL 182 
clearance. 183 
Adipocytes create a tumour-suppressive niche in ALL 184 
To explore the possibility that variations of adipocyte activity within the BMM   contribute a 185 
meaningful  pathophysiological role  vs merely serving as a by-product of the leukaemic 186 
process, functional studies were performed to establish  the effects of adipocyte stroma on 187 
ALL cells using an in vitro co-culture strategy employing  primary human adipocytes 188 
differentiated from healthy BM-MSCs or adipocytes derived from murine 3T3-L1 cell lines 34 189 
together with ALL cell lines; Nalm-6, REH and RS4;11 (Fig. 3a). 190 
Surprisingly, we observed that both 3T3-L1 and primary BM-MSC adipocytes robustly 191 
impaired the growth capacity of independent ALL cell lines with high reproducibility 192 
compared to log phase monocultures (Fig. 3b), with evidence of a dosage-dependent 193 
effect, as indicated by lower relative growth rates in 3T3-L1 adipocyte conditions that have 194 
more complete adipocyte conversion (Supplementary Fig. 3a). Notably, basal growth of 195 
ALL cell lines was unaffected by coculture with primary osteoblasts, primary BM-MSCs and 196 
3T3-L1 pre-adipocytes, confirming that adipocytes inhibited in vitro ALL growth in a tissue-197 
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specific manner and that this was a direct causal effect. Mechanistically, we confirmed that 198 
adipocyte niches did not lead to appreciable apoptosis (Supplementary Fig. 3b) but instead 199 
antagonized cell cycle progression, resulting in reproducible expansion of a quiescent cell 200 
pool accompanied by variable reductions in S/G2/M progression (Fig. 3c). Thus, interaction 201 
with adipocyte niches in vitro suppresses the constitutive proliferation of ALL cells and 202 
lowers cell cycle transit in a causal manner. Furthermore, these data confirm that in vitro 203 
murine 3T3-L1-derived adipocytes 34 robustly recapitulate key responses of primary BM-204 
adipocyte tissue cultures thereby establishing the reliability of these models as an 205 
experimental system. As a further validation, adipocytes derived from BM-MSCs obtained 206 
after remission induction were also assessed and were shown to induce similar outcomes to 207 
those of healthy BM-MSC primary adipocytes (Supplementary Fig. 3c), thus extending the 208 
relevance of the described effects to the post treatment context. 209 
To investigate the importance of these data in an in vivo context, experiments were 210 
conducted using xenotransplanted primary B-ALL tumours of both leukaemic cell lines and 211 
primary patient samples (n=4), comparing in vivo ALL development in adipocyte-rich (tail-BM 212 
and gonadal fat) vs adipocyte-poor (femur) tissues (Fig. 3d) . We included gonadal fat based 213 
on findings in 3T3-L1 adipocytes, a non-BM restricted tissue, suggesting that there was no 214 
difference in adipocyte functionality in terms of executed effects on ALL cells. We first 215 
confirmed that NSG strains have low BM adipocyte abundance in femoral BM, as 216 
demonstrated by osmium tetroxide staining (Fig. 3e), validating the study of femoral BM as a 217 
model of adipocyte-poor marrow. We found that both the xenotransplanted Nalm-6 ALL cell 218 
line (Fig. 3f) and primary ALL cells from four genetically distinct tumours (Fig. 3g) had 219 
significantly less leukaemia cell engraftment in all adipocyte-rich tissues at 3-4 and 6-8 220 
weeks following transplantation respectively when compared to adipocyte-poor femoral BM, 221 
which demonstrated robust leukaemia engraftment at this time. Thus, consistent with the 222 
functional outcomes in vitro (Fig. 3b), ALL cells in vivo demonstrated limited expansion in 223 
adipocyte niches. Further direct phenotypic characterization of engrafted tumours confirmed 224 
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that ALL cells resident in adipocyte niches were marked by increased cellular quiescence 225 
(Fig. 3h and 3i) and reduced cell cycle G1/S/M status, substantiating the concept that 226 
adipocytes support tumour dormancy states. These results represent a broader biological 227 
relationship with ALL than previously described24 and are in line with reported effects in 228 
HSCs35. 229 
Taken together, these data conceptualize adipocytes as key drivers of ALL cell plasticity and 230 
switchers of cellular fate from constitutive proliferator status to a phenotype characterised by 231 
proliferative quiescence. These data support the concept that changes in BM-adipocyte 232 
population dynamics facilitate ALL in distinct ways. Compromised adipocyte activity, possibly 233 
through ALL cells actively deregulating adipocyte generation, eliminates a key inhibitory 234 
niche for ALL, thereby enabling the emergence of leukaemia. However, reinstated adipocyte 235 
activity during the treatment response evolves a pro-tumour dormancy setting that could 236 
participate in antagonizing chemotherapy targeting. 237 
Adipocyte niches restrict protein synthesis in ALL via non-canonical factors 238 
We next sought to define the mechanism(s) underlying the dormancy/growth suppressive 239 
response of ALL cells to microenvironmental adipocytes. We selected 3T3-L1 adipocyte 240 
models to initialize these studies based on their strong recapitulation of the BM-adipocyte 241 
interplay (Fig. 3b and 3c) and the ability to control for major confounding effects, e.g., 242 
nonadipocyte stromal-cell contamination (Supplementary Fig. 3a), thus, overcoming the 243 
principal limitation of in vivo adipocyte niche systems 36. 244 
Initial assessments confirmed that a cell cycle checkpoint mechanism was not engaged in 245 
adipocyte-conditioned ALL cells (Supplementary Fig. 4a), suggesting that the phenotypic 246 
response of ALL cells to the adipocyte stroma likely occurs through an indirect vs a direct 247 
effect on the cell cycle. Next, given that lipid crosstalk is the principal mode of adipocyte-248 
tumour cell interplay described to date 37-39, we assessed the contribution of these events to 249 
the adipocyte specific effects on ALL. Lipid profiling studies established that +24 hrs 250 
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following  3T3-L1 adipocyte coculture, Nalm-6 cells demonstrated an accumulation of 251 
intracellular lipids, the components of which included oleic acid, a major subclass of fatty 252 
acid, which resulted, in part, from direct transfer of fatty acid from adipocytes to ALL, 253 
consistent with previous reports 37-39. However, further functional evaluation of  the fatty acid 254 
flux pathway confirmed that this was not a major factor driving ALL growth suppression 255 
(Supplementary Fig. 4b-4j and Supplementary Discussion). Given that these candidate 256 
mechanisms could not robustly account for the adipocyte-ALL interplay, we next turned to 257 
unbiased screens. Here, we reasoned that the rapid adaptive response of ALL cells (Fig. 3b) 258 
suggests that global signalling and transcriptional networks were being stimulated. We 259 
therefore subjected Nalm-6 cells cocultured with 3T3-L1 adipocytes to quantitative LC-260 
MS/MS phosphoproteomic analysis at two timepoints (+24 h and +72 h), comparing 261 
outcomes between 3T3-L1 preadipocyte coculture to control for general stromal effects. At 262 
both timepoints, we detected a substantial impact of adipocyte conditions on the ALL 263 
phosphoproteome (log2 FC≥1 or log2 FC≤-1, p-value≤0.05) involving 1,808 and 981 264 
phosphorylation sites at +24 h and +72 h, respectively (Fig. 4a), consistent with large-scale 265 
rebalancing of these networks. Gene Ontology (GO) enrichment analysis was conducted on 266 
these significantly modulated phosphosites (Fig. 4b), revealing that at +24 h, terms related 267 
to biosynthetic and metabolic processes inclusive of lipid metabolism (e.g., lipid metabolic 268 
process, triglyceride catabolic process) were overrepresented, likely reflecting the ensuing 269 
effects of lipid translocation from 3T3-L1 adipocytes at this time (Supplementary Fig. 4b 270 
and 4c). In addition to these expected modulations, pathways relating to diverse aspects of 271 
protein homeostasis (protein translation, translation initiation, elongation “proteostasis”) and 272 
mRNA processing were significantly overrepresented in adipocyte-modulated ALL cells at 273 
both +24 hr and +72 hr, albeit switching from upregulation to repression over time. Notably, 274 
kinase-substrate enrichment analysis (KSEA), a platform to systematically infer the 275 
activation of given kinase pathways from mass spectrometry-based phosphoproteomics 40, 276 
identified a general increase in proliferation-associated signalling networks, e.g., MAP2K1 277 
JAK2, at +24 h despite robust suppression of cell growth (Supplementary Fig. 4k), 278 
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indicating that mitogenic signalling was not acutely disrupted to explain the acute growth 279 
suppression. 280 
Gene expression profiles of adipocyte-cultured Nalm-6 cells at +24 hr assessed by RNAseq 281 
indicated predominantly low-magnitude changes (Fig. 4c, Supplementary Fig. 4l and 4m) 282 
with the difference in the adipocyte imprinted Nalm-6 transcriptome (adjusted p-value < 0.05) 283 
defined by only 547 genes, of which only a low number of genes (n=50) met conventional 284 
DEG thresholds of log2 FC ≥ 1 or log2 FC ≤ -1.GSEA revealed few overrepresented 285 
pathways (Fig. 4d), namely, glycolysis (p-value<0.05, FDR q-value=0.03) and its 286 
subcomponent fructose biosynthesis (p-value<0.05, FDR q-value=0.03), likely reflecting the 287 
altered intracellular lipid environment (Supplementary Fig 4b and 4c). Notably, and in line 288 
with the phosphoprotetomics data, functions related to mRNA processing and multiple 289 
aspects of protein homeostasis (folding, amino acid metabolism, translation, ribosome 290 
biogenesis) were common pathways most underrepresented, as well as G2/M gene sets, as 291 
expected. 292 
Together, these comparative results indicate that the acute response of ALL cells to 293 
adipocyte stimulation is characterized by significantly altered phosphorylation networks and, 294 
to a lesser extent, transcriptional events affecting cellular metabolism, a predicted outcome 295 
of ALL-adipocyte interaction, as well as major unanticipated effects on posttranscriptional 296 
processes and the protein translation network. 297 
Given that protein homeostasis is a major cellular process modified by the adipocyte stroma, 298 
we next assessed its significance functionally by assessing its endpoint, global protein 299 
translation, using the O-propargyl-puromycin (OP-Puro) incorporation assay as a label of 300 
translational activity. The results demonstrated that compared to both control conditions, 301 
monoculture and 3T3-L1 preadipocytes, Nalm-6 ALL cells subjected to 3T3-L1 adipocyte 302 
coculture demonstrated strikingly lower OP-Puro incorporation, with very low technical and 303 
biological variability, achieving translational attenuation similar to that of cycloheximide 304 
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(CHX), a robust inhibitor of protein translation (Fig. 4e). Similar outcomes were achieved in 305 
other ALL cell lines (Supplementary Fig. 4n), indicating that lowered rates of protein 306 
synthesis were not cell line specific. Importantly, differences in OP-Puro incorporation were 307 
not due to loss of fluorescence, which we confirmed occurred much later; 3 h after OP-puro 308 
administration (Supplementary Fig 4o). Moreover, there was no increased clearance of 309 
OP-puro containing polypeptides (Supplementary Fig. 4p) and no saturation in the OP-puro 310 
signal (Supplementary Fig. 4q). Furthermore, a similar loss of OP-Puro incorporation was 311 
also found in ALL cells cocultured with primary BM-MSC-derived adipocytes 312 
(Supplementary Fig. 4r), confirming that this was a relevant biological interaction not just 313 
restricted to the 3T3-L1 model system. 314 
Next, to test whether differences in OP-puro are explained by differences in the cell cycle, 315 
we assessed OP-puro according to DNA content. We found that 3T3-L1 adipocytes still 316 
imposed significantly lower protein synthesis in ALL cells in both G0/G1 and S/G2/M (Fig. 4f 317 
and Supplementary Fig. 4s). Therefore, lower rates of protein synthesis in ALL cells were 318 
not simply a consequence of increased quiescence. Importantly, these findings were also 319 
consistent with analyses performed using human ALL samples in vivo. Two primary ALL 320 
tumours (ALL24 and ALL25) previously validated as growth repressive/dormancy responsive 321 
to in vivo adipocyte microenvironments (Fig. 3g and 3i) were subjected to repeated 322 
xenografting followed by ex vivo staining with OP-Puro. We found that primary ALL cells in 323 
vivo also demonstrated restricted protein translation in adipocyte-rich niches independent of 324 
the cell cycle stage (Fig. 4g), thus recapitulating the findings obtained with ALL cell lines in 325 
vitro; however, the effect was of lower magnitude, possibly due to some recovery of protein 326 
translation following a longer period of microenvironmental extraction. 327 
Taken together, these data demonstrate that adipocyte microenvironments restrict the level 328 
of protein synthesis in ALL cells. Such reports are of particular interest because modulating 329 
protein synthesis is unique among prior reports of regulatory mechanisms involving 330 
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adipocyte niches 31,37,39,41,42. Furthermore, this observation directly raises the possibility that 331 
adipocyte-mediated cell cycle failure and ALL growth suppression reflect a limitation 332 
imposed by low proteome flux 43. 333 
To address this hypothesis, we first explored the mechanism of adipocyte-mediated 334 
hypotranslation using the 3T3-L1 adipocyte system. Assessment of general translation 335 
determinants established that there were no acute changes in cell diameter 336 
(Supplementary Fig. 4t) or compromise of transcriptional output (total RNA content, 18S or 337 
28S ribosomal RNA) (Supplementary Fig. 4u) that explained the loss of translational 338 
output. Moreover, key signalling pathways representing major control points for protein 339 
translation, namely, mTOR 44 and the endoplasmic reticulum stress-induced (ER) unfolded 340 
protein response plus correlated integrated stress response (ISR) pathways 45, were not 341 
selectively engaged in ALL cells (Supplementary Fig. 4v) to explain the repression in 342 
protein translation. In line with this, there was no evidence of ER stress gene activation by 343 
either RNAseq (Fig. 4d) or RT-qPCR (Supplementary Fig. 4w). Thus, on the basis of 344 
these orthogonal assessments, 3T3-L1 adipocytes appear to modify ALL proteome flux via 345 
factors independent of canonical translation cascades, possibly suggesting that adipocytes 346 
execute their regulatory effects on protein translation via a distinct process. 347 
To further establish whether ALL suppression is a consequence of adipocyte-mediated 348 
translational repression, we turned to pharmacological approaches that modulate the level of 349 
protein translation. Of drugs known to increase protein translation (ISRIB, PERKi, or 350 
GCN2ib), only GCN2ib led to effective target modulation (repressed eIF2α phosphorylation) 351 
when tested in Nalm-6 cells (Fig. 4h), and we therefore progressed this drug to testing in 352 
3T3-L1 adipocyte coculture. We observed that the addition of GCN2ib led to a partial but 353 
notable increase in protein translation in ALL cells (Fig. 4i), which was associated with a 354 
significant reduction in adipocyte-associated ALL cell quiescence (Fig. 4j). Although GCN2ib 355 
did not induce measureable short-term growth effects (Supplementary Fig. 4x), the latter 356 
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may reflect that rescue of protein translation was incomplete. Altogether, these data 357 
establish a causal association between lowered protein translation status in ALL cells and 358 
adipocyte-imposed ALL quiescence and underscore how subversion of a key housekeeping 359 
function contributes to the establishment of a therapy-adverse state. 360 
Adipocyte-adapted ALL proteomes increase global stress resistance 361 
While adipocytes are known to contribute to chemoresistance via diverse mechanisms 362 
14,17,19,22 23-27, the link between ALL resistance and ALL hypotranslational states is least 363 
explored. In particular, given our finding that adipocyte-induced translational loss affects ALL 364 
tumours as a whole and involves all cell cycle stages (Fig. 4f), these data suggest that 365 
adipocyte niches may not exclusively protect leukaemia cells by maintaining them in the 366 
quiescent phase  24. 367 
To directly address whether adipocyte niches provide protective outcomes independent of 368 
target cell quiescence, we challenged Nalm-6 ALL cells with both cell cycle-dependent 369 
chemotherapeutics, an accepted instigator of quiescence-driven chemoresistance, and 370 
mitotic state-independent stresses induced by hydrogen peroxide or withdrawal of FBS. The 371 
latter would not be expected to drive differential outcomes based on target cell dormancy. 372 
Intriguingly, despite significantly reduced proteome flux, adipocyte-cultured ALL cells had 373 
increased cellular fitness against both cell cycle-dependent chemotherapy and mitotic state-374 
independent stressors, although as expected, the outcomes were dependent on the 375 
individual stressors involved (Fig. 5a). Thus, adipocytes instigate more generalized cellular 376 
fitness in ALL cells beyond induction of cellular quiescence, which may relate to their global 377 
effect on protein translation. 378 
In support of this notion, ALL cells were resensitized to chemotherapy and partially also to 379 
mitotic state-independent stressors following prolonged (+48 hr) microenvironmental 380 
extraction (Fig. 5b), when protein biosynthetic activity and quiescence levels had normalized 381 
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(Supplementary Fig. 5b). The possibility to pharmacologically modulate the adipocyte-382 
imposed restrictions on the ALL proteome using GCN2ib (Fig. 4i) offered the opportunity to 383 
test its putative contribution to cellular fitness.  Therefore, we used GCN2ib to rescue protein 384 
translation in coculture prior to applying various cellular stresses. We observed that under 385 
GCN2ib treatment, the cytoprotective effect of adipocytes on ALL cells was decreased in 386 
response to cell cycle-dependent chemotherapy, as anticipated (Fig. 4j); however, we also 387 
observed a notable reduction in cytoprotection against mitotic state-independent stress 49-388 
65% (mean ± SEM: 57% ± 2.4) (Fig. 5c). These observations indicate that adipocytes likely 389 
enable the survival of ALL cells via 2 distinct processes: induction of cellular quiescence and 390 
its wider suppression of protein translation. 391 
Finally, we investigated the possibility that adipocyte-mediated stress protection is 392 
accompanied by activation of selective mRNA translation of proteins required for stress 393 
mitigation 45. To investigate this hypothesis, we subjected Nalm-6 cells under 3T3-L1 394 
adipocyte coculture to pulsed stable isotope chromatography-mass spectrometry (SILAC)-395 
based proteomic analysis (Fig. 5d). As expected, we confirmed potent repression of global 396 
protein synthesis (Fig. 5e). Of the 470 proteins identified, 413 (87.5%) were robustly cross-397 
identified as focally downregulated at both +24 h and +48 h. These co-downregulated 398 
proteins were enriched for pathways related to translational regulation, ribosomal assembly 399 
and mRNA processing (Table 1), reflecting a widespread influence on the translational 400 
network. Notably, we did not detect a high abundance of proteins related to selective mRNA 401 
translation (n=7), suggesting that preferential mRNA translation was not actively engaged. 402 
Thus, we conclude that adipocyte-induced translational reprogramming accompanies a pro‐403 






Our study highlights several important findings. First, the adipocyte niche is dynamic in ALL, 408 
evolving from depleted states in ALL disease to full reconstitution during the remission 409 
response, confirming that these niches contribute temporally to an MRD-associated 410 
environment. Second, we identified a protein-based interplay regulated by the adipocyte 411 
stroma that restricts protein translation in ALL cells. Importantly, adipocyte-imposed 412 
restriction of protein translation played a direct role in regulating ALL cell quiescence. To the 413 
best of our knowledge, this is the first report to link the regulation of ALL quiescence with 414 
extrinsically mediated control of protein synthesis, although a similar parallel has been 415 
reported for HSCs involving exogenous angiopoietin 46. Consistent with our findings, the 416 
level of translational activity has also been shown to regulate HSC maintenance 47  further 417 
emphasising the connection between quiescence-proliferation decisions and protein 418 
dynamics. We further show that reduced levels of global protein synthesis are associated 419 
with increased cellular fitness in ALL cells (Fig. 5a-5c) and that this protection was not 420 
limited to the feature of cellular quiescence but encompassed broader multitrait resistance. 421 
In this way, adipocytes act not as selective cell survival factors but as providers of broader 422 
tumour cell protection than previously envisaged 48. Notably, our finding that adipocytes 423 
enhance the survival and persistence of ALL cells through non-cell-autonomous suppression 424 
of the ALL proteome resonates with a form of biosynthetic stress resilience that has recently 425 
gained recognition as a cell-intrinsically determined process 49, emphasizing the importance 426 
of adapted biosynthetics as a critical mark of treatment resistance. How adipocyte-imposed 427 
hypotranslation leads to improved multistress resistance in ALL cells was not attributable to 428 
a switch to selective translation of prosurvival proteins, as reported for other protein 429 
suppression states44,45. This opens up the conceptual possibility that other factors, such as 430 
enhanced proteome quality, may play a contributing role, analogous to paradigms in other 431 
model organisms 50. Although these aspects are yet to be resolved, the observation that 432 
adipocyte-regulated loss of protein translation in ALL cells promotes ALL resistance adds to 433 
the increasing repertoire of stromal mechanisms that present a challenge to therapeutic 434 
success. In vivo targeting of adipocytes should provide further insight into this process but 435 
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was not applied here due to the inability to modulate BM adipocytes exclusively without 436 
introducing significant confounding variables 51-53. Therefore, appropriate model 437 
development will be essential to overcome this limitation and to establish the full in vivo 438 
potential of adipocytes in ALL disease/resistance. 439 
Although our results implicate GCN2 as the potential factor determining ALL translational 440 
repression, given its rescue when GCN2 is inhibited (Fig. 4i), the lack of any selective 441 
increase in eIF2α phosphorylation under adipocyte conditions (Supplementary Fig. 4v) 442 
together with no orthogonal features of activated ISR downstream (Fig. 4d and 443 
Supplementary Fig. 4v-w) as well as incomplete phenotype reversal despite potent eIF2α 444 
inhibition argue against this being a principal driver. We predict that the mechanism coupling 445 
adipocytes with the leukaemia proteome is complex and beyond the scope of this report 446 
given that canonical pathways controlling protein translation were not obvious. Significantly, 447 
our data do yield important insights into potential entry points for therapeutic intervention. 448 
First, therapeutic modulation of GCN2 54 may disrupt the regulatory impact of adipocytes on 449 
ALL protein synthesis, thereby limiting the development of ALL cell phenotypes deleterious 450 
to the therapy response. Second, the interactome between ALL and adipocytes (Fig. 1f) was 451 
a critical effector of adipocyte-induced hypotranslation states (Supplementary Fig. 5c and 452 
5d) and therefore represents a further strategy to disrupt ALL-adipocytic cross-talk (Fig. 1f). 453 
Further work is warranted to deeply characterise the adipocyte-ALL interactome to pursue 454 
this potentially profitable avenue. The tractability of such approaches is supported by our 455 
data, which demonstrates that both proliferation loss and lowered proteome flux are 456 
reversible states upon microenvironmental withdrawal (Supplementary Fig. 5d). 457 
Our results merit comparison with the wider published data relating to adipocyte niches and 458 
leukaemia. While our data are in broad agreement with reports demonstrating that adipocyte 459 
stromal microenvironments are active modulators of the tumoural phenotype, the 460 
tremendous potential for these stroma to elicit both tumour- and tissue-dependent outcomes 461 
is also specifically highlighted. 462 
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In AML, where specifically evaluated, the adipocyte stroma has been shown to enhance 463 
AML proliferation as well as cellular survival 37, similar to reported effects in various solid 464 
cancers 38,55,56. In line with this, adipocytes located in gonadal tissue play a supportive role in 465 
CD36+ AML leukaemia stem cell (LSC) maintenance and expansion 39. The main 466 
mechanism defining the adipocyte-AML interplay relates to facilitated fatty acid transfer37,39. 467 
As our descriptions appear diametrically opposite, both in terms of the effect of adipocytes 468 
on cellular growth, the role of fatty acids and the nature of the modulation, which is a 469 
contextual and reversible property of interactions with adipocyte niches, this supports the 470 
notion of lineage specificity  in adipocyte niche function. Thus, while adipocyte depletion 471 
states are characteristic of AML disease 31,57 as well as other conditions, its biological 472 
significance will be defined by the interplay specific to the tumour cell type. Our study defines 473 
a conceptual framework (Fig. 6) specific to the B-ALL disease-remission transition, based on 474 
the interplay demonstrated with adipocyte stroma and should not be directly extrapolated to 475 
other conditions exhibiting BM-adipocyte dynamics. 476 
 477 
Overall, our report provides insights into the versatility of adipocytes in their capacity for 478 
tumour adaptation. The functional coupling between adipocytes and ALL proteomes goes 479 
beyond known players of adipocyte-tumour cell interplay and represents an important 480 















Human samples 492 
The use of human samples, collection and publication of individual-level clinical data was 493 
approved by the NRES Committee London; City & East Research Ethics Committee 494 
10/H0704/65. The conduct of the study was fully compliant with the ethical approval. 495 
Pretreatment bone marrow and peripheral blood samples containing >80% blasts were 496 
collected from adult patients with ALL at diagnosis and cryopreserved after mononuclear 497 
cell (MNCs) isolation using Lymphoprep™ (07851, STEMCELL Technologies) based 498 
density gradient centrifugation. Patient- and disease-specific features are summarized in 499 
Supplementary Table 3. Adult healthy control BM-MNCs were purchased from Lonza (2M-500 
125C) (median age: 27 years, range: 21-47). BM trephine biopsies were obtained from the 501 
posterior iliac crests of patients as part of routine diagnostic procedures and were sourced 502 
from the diagnostic laboratories of St Bartholomew’s, Royal Marsden and Christie Hospitals 503 
U.K . Healthy trephines were selected from adult lymphoma staging biopsies where 504 
histological involvement had been excluded. Peripheral blood stem cells were obtained from 505 
GCSF-mobilized healthy donors (GMPB) who were undergoing an allogeneic stem cell 506 




Histological analysis 511 
Quantitative analysis of adiposity in patient diagnosis, remission (<5% marrow blasts defined 512 
morphologically) and healthy control trephine biopsies was determined using a custom 513 
analysis protocol package (APP) designed using AuthorTM (Visiopharm). In brief, 514 
formaldehyde-fixed paraffin-embedded sections of human trephine biopsies were stained 515 
with haematoxylin and eosin (H&E) to visualize the gross anatomy of BM tissue. Whole H&E 516 
slides were scanned using a Pannoramic 250 Flash at 20x magnification and then imported 517 
into Visiopharm software. Regions of interest (ROIs) consisting of the haematopoietic 518 
marrow space were delineated. Trabecular bone, areas of haemorrhage, processing or 519 
tissue damage artefacts or non-marrow adipocytes were excluded from analysis. ROIs were 520 
verified by expert histopathological review. Filters were applied to the input image combining 521 
median, standard deviation and multiplication of pixel neighbourhoods followed by threshold 522 
analysis to distinguish the empty adipocytes from the background tissue. Post-processing 523 
scripts based on minimum and maximum area and form factor further restricted 524 
measurement to only adipocytes. A separation script was applied to distinguish individual 525 
adipocytes arranged in clusters. Output variables from the APP were adipocyte count and 526 
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size along with the input area of the ROI. Immunostaining of BM trephines was performed on 527 
four μm slides for CD79a (clone SP18, Roche), CD34 (QBend 10, Roche), CD22 (clone 528 
SP104, Roche), Tdt (5267811001, Roche) and PAX5 (EPR3730, Abcam,). Staining was 529 
performed on the Ultra Ventena platform using the Optiview DAB detection kit (Roche 530 
760700). Proximity relationships between drug resistant cells and adipocytes were 531 
determined by 2 independent assessors and verified by an expert haematopathologist. Only 532 
consensus events were reported. 533 
 534 
Adiponectin testing 535 
BM serum samples were collected from patients with newly diagnosed ALL before the 536 
initiation of treatment. For control samples, BM serum was utilized from two sources: 537 
patients with <stage III diffuse large B cell lymphoma without BM involvement (n=5) or 538 
healthy donors (n=2). Adiponectin measurements were performed in technical duplicate 539 
using the commercial RayBio® Human Adiponectin ELISA kit (ELH-Arcp30). 540 
 541 
Generation of mesenchymal stromal cells 542 
BM-MNCs were seeded at densities of 10x106 cells per 175 cm2 in MesenCult™ MSC 543 
Basal Medium (05401, STEMCELL Technologies) supplemented with MesenCult™ MSC 544 
Stimulatory Supplement (05402, STEMCELL Technologies), 100 units/ml penicillin and 100 545 
µg/ml streptomycin (15140122, Thermo Fisher Scientific), 2 mM L-glutamine and 1 ng/ml 546 
recombinant human FGF (233-FB, R&D Systems) and incubated at 37°C and 5% CO2 547 
under humidified conditions for 21 days. The culture medium was changed on day 2 and 548 
every week thereafter to remove nonadherent cells. On day 21, adherent cells, 549 
corresponding to BM-MSC populations at P1, were detached using a Trypsin/EDTA 550 
Solution (R001100, Thermo Fisher Scientific) and counted using the LUNA-FL™ Dual 551 
Fluorescence Cell Counter (Logos Biosystems) and Acridine Orange/Propidium Iodide 552 
Staining (F23001, Logos Biosystems). A subset was subjected to phenotypic 553 
characterization using the Human MSC Analysis Kit (562245, BD Biosciences) to ascertain 554 
whether the criteria defined by the International Society for Cellular Therapy were met: 555 
≥95% expression of CD73, CD90 and CD105 and ≤2% expression of the haematopoietic 556 
and endothelial cell markers CD34, CD45, CD11b, CD19 and HLA-DR 30. The rest of the 557 
cells were passaged to a maximum of P4. 558 
 559 
Colony-forming unit fibroblast (CFU-F) assays 560 
For CFU-F assays, BM-MNCs were plated in duplicate or triplicate at densities of 1x106 cells 561 
per 25 cm2 flask and cultured as described under “Generation of Mesenchymal Stromal 562 
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Cells”. After 10 days, colonies (>50 cells) corresponding to CFU-F were stained with 0.5% 563 
crystal violet (C6158, Merck KGaA) and counted by light microscopy 58. 564 
 565 
MSC differentiation 566 
The ability of MSCs to differentiate into multiple mesenchymal lineages was examined using 567 
the Human Mesenchymal Stem Cell Functional Identification Kit (SC006, R&D Systems). All 568 
differentiation studies were undertaken at the P2-P3 stage, and MSCs were cultured in 569 
MEM α medium (22561021, Thermo Fisher Scientific) supplemented with 10% heat-570 
inactivated foetal bovine serum (FBS; 10500064, Thermo Fisher Scientific), 100 units/ml 571 
penicillin, 100 µg/ml streptomycin and 2 mM L-glutamine prior to inducing differentiation. 572 
Adipogenic differentiation was initiated in confluent MSC cultures by adding adipogenic 573 
differentiation medium containing 1% adipogenic supplement. For osteogenic 574 
differentiation, MSCs were grown to 60-70% confluence prior to initiating osteogenic 575 
differentiation using osteogenic differentiation medium containing 5% osteogenic 576 
supplement. The culture medium was refreshed every 3 days for a total duration of 21 days, 577 
after which differentiated MSC cultures were set up for coculture. For immunofluorescence 578 
studies, MSCs were differentiated on sterile glass coverslips. For osteogenic differentiation, 579 
coverslips were coated with 1 µg/ml fibronectin (1918-FN, R&D Systems) to prevent cell 580 
detachment. Differentiated cells were fixed with 4% PFA for 20 min followed by washes in 581 
DPBS (no calcium, no magnesium; 14190094, Thermo Fisher Scientific). Cells were 582 
permeabilized and blocked with 0.1% Triton X-100 and 2% BSA (A9647, Merck KGaA) in 583 
DPBS for 45 min prior to incubation with either an unconjugated goat polyclonal antibody 584 
recognizing FABP4 (10 μg/mL; AF1443, R&D Systems) followed by a donkey anti-goat 585 
antibody conjugated to Alexa-647 (1:500; A-21447, Thermo Fisher Scientific) or an 586 
unconjugated mouse monoclonal antibody against osteocalcin (10 μg/mL; MAB1419, R&D 587 
Systems) followed by a goat anti-mouse antibody conjugated to Alexa-488 (1:500; A-11001, 588 
Thermo Fisher Scientific) to identify adipocytes and osteoblast cells, respectively. Slides 589 
were mounted with ProLong™ Gold Antifade Mountant with DAPI (P36931, Thermo Fisher 590 
Scientific), and fluorescent images were acquired at 20x magnification using a Nikon 591 
Eclipse Ci fluorescence microscope. Images were analysed with ImageJ software (v1.50b, 592 
USA). At least five independent fields (>50 cells) per differentiation condition were used to 593 
quantify the frequency of DAPI/FABP4-stained adipocytes or DAPI/osteocalcin-stained 594 
osteoblasts. 595 
 596 
Conditioned medium (CM) collection 597 
ALL cell lines (Nalm-6, REH, RS4;11) and three independent healthy human GCSF-598 
mobilized peripheral blood (GMPB) samples enriched for haematopoietic stem cells were 599 
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cultured in RPMI and 10% FBS for +72 h prior to supernatant collection. The cell viabilities 600 
prior to CM collection were >85%. Supernatants were filtered and centrifuged to eliminate 601 
cells and cell debris. Each CM was then aliquoted in a volume 5 ml with the addition of 50 µl 602 
of adipogenic supplement before being frozen at -80°C prior to use. No CM controls were 603 
derived from RPMI, and 10% FBS cultured alone at +72 h was treated similarly. 604 
Precollected CM and non-CM controls were then utilized to induce adipogenic differentiation 605 
in P3 healthy MSCs, with medium changes as detailed under “MSC differentiation”. 606 
 607 
Oil red O staining 608 
Oil red staining was performed by fixing cells with 4% PFA and then incubating them with 609 
60% isopropanol for 5 min prior to staining with 0.3% oil red O (O0625, Sigma-Aldrich) in 610 
60% isopropanol for 10 min at room temperature (RT). Cells were washed with distilled 611 
water to remove excess dye and counterstained with Mayer's haematoxylin. Digital images 612 
were acquired using a Nikon Eclipse Ci microscope. To quantify the staining intensity, oil 613 
red was eluted in isopropanol, and absorbance was measured at a wavelength of 500 nm 614 
using a FLUOstar Omega (BMG Labtech) microplate reader. 615 
 616 
RNA sequencing 617 
Total RNA was extracted from P4 ALL and healthy BM-MSCs as well as Nalm-6 cells 618 
cocultured with 3T3-L1 preadipocytes or 3T3-L1 adipocytes using the RNeasy mini kit 619 
(74104, Qiagen). RNA-seq was performed using NextSeq™ 500 High Output Run (150 620 
cycles) with 40-50 million reads and 150 bp reads paired end. RNA-seq was performed in 621 
one technical run for the BM-MSC samples and in two technical runs for the Nalm-6 cells. 622 
RNA-Seq reads were aligned to the human genome (hg38) using Hisat2. Count files were 623 
generated by mapping reads to the human genome (hg38) p5 using HTSeq. Differential 624 
expression analysis was performed using Limma for BM-MSC RNA-seq and DESeq2 in R 625 
for Nalm-6 cell RNA-seq. The p-values were further adjusted using the Benjamini and 626 
Hocheberg procedure. Gene set enrichment analysis (GSEA) was performed using GSEA 627 
software version 2.1.0 (Broad Institute) and the FGSEA package in R (Broad Institute). 628 
Comparisons were made using curated (C2) gene set collections from the Molecular 629 
Signatures Database (MSigDB). The Ggplot2 package in R was applied to visualize the 630 
results. Publicly available gene expression data sets were used to compare gene 631 
expression profiles between mature human osteoblasts and adipocytes (GSE945129). Heat 632 
map generation was performed using individual probe sets. The array data have been 633 





Cell lines 637 
The human ALL cell lines Nalm-6 (CRL-3273), REH (CRL-8286) and RS4;11 (CRL-1873) 638 
were purchased from ATCC (American Type Culture Collection, Rockville, MD). ALL cell 639 
lines were cultured in RPMI 1640 medium (2187534, Thermo Fisher Scientific) 640 
supplemented with 10% FBS, 100 units/ml penicillin and 100 µg/ml streptomycin. 641 
The murine fibroblast cell line 3T3-L1 (CL-173) was purchased from ATCC. 3T3-L1 cells 642 
were cultured in DMEM (41966029, Thermo Fisher Scientific) supplemented with 10% FBS, 643 
100 units/ml penicillin and 100 µg/ml streptomycin. 644 
All cells were incubated at 37°C and 5% CO2 under humidified conditions and were 645 
routinely subjected to mycoplasma testing. Cell counts and viability measurements were 646 
performed with the LUNA-FL™ Dual Fluorescence Cell Counter (Logos Biosystems) using 647 
acridine orange/propidium iodide stain (F23001, Logos Biosystems). 648 
 649 
3T3-L1 adipocyte differentiation 650 
3T3-L1 preadipocytes were differentiated into adipocytes according to standard methods 651 
with slight modifications 59,60. Briefly, two days post confluency (Day 0), DMEM (containing 652 
10% FBS and antibiotics) was supplemented with 0.5 mM 3-isobutyl-1-methylxanthine 653 
(I7018, Merck KGaA), 0.25 μM dexamethasone (D2915, Merck KGaA), 2 μM rosiglitazone 654 
(R2408, Merck KGaA) and 1 μg/ml insulin (I9278, Merck KGaA). After 48 h (Day 2), the 655 
medium was replaced with DMEM supplemented with 10% FBS, 1 μg/ml insulin and 656 
antibiotics. The medium was subsequently changed to DMEM supplemented with 10% FBS 657 
and antibiotics every 2 days until day 10, after which cells were utilized for coculture 658 
experiments. The adipocyte conversion at this time was reproducibly 100%, as 659 
demonstrated by adipocyte specific FABP4 immunofluorescence staining (Supplementary 660 
Fig. 3a). 661 
 662 
ALL coculture experiments 663 
Fully confluent stromal cultures were washed twice with DPBS to remove differentiation 664 
media prior to adding ALL cell line suspensions to RPMI medium containing 10% FBS and 665 
antibiotics. For 150 mm culture dishes, the seeding density was 10x106 ALL cells in 30 ml 666 
media, and for 6-well plates, 0.5x106 ALL cells were seeded in 5 ml medium. The ratio of 667 
stromal cells to ALL cells at the time of coculture was consistently 1:2. For assaying cell 668 
number and cell cycle status, the full contents of cocultures, including stromal elements, 669 
were collected by flushing the wells with DPBS prior to flow cytometry analysis. To isolate 670 
ALL cells for reculture or RNA and protein extraction, cocultures were subjected to light 671 
trypsinization with a 50% diluted trypsin/EDTA solution for 1 min, followed by repeated 672 
washing with DPBS and gentle pipetting to remove supernatant and avoid disturbance of 673 
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the stromal monolayer. Purity assessment of these supernatants by flow cytometry 674 
confirmed that stromal cell contamination was reproducibly <5%. 675 
In specified experiments, coculture was performed in the presence of drugs added 2 hr after 676 
the coculture was set up corresponding to when ALL cells were fully adherent to the 677 
adipocyte stroma. The added drugs were 20 µM SSO (sulfo-N-succinimidyl oleate sodium; 678 
SML2148, Merck KGaA), 40 µM etomoxir (E1905, Merck KGaA), 30 µM BMS309403 (5258, 679 





Flow cytometry 685 
Flow cytometry was performed on an LSRFortessa™ flow cytometer (BD Biosciences). 686 
Data were analysed by FlowJo (version 10.1, Tree Star). Antibody staining was performed 687 
for 15 min in the dark. DAPI (D3571, Thermo Fisher Scientific, 1:2,000 in DPBS containing 688 
2% FBS) was added prior to flow cytometric analysis. Gates were set up to exclude 689 
doublets, nonviable cells (DAPI+, or fixable viability dye+) and isotype-stained populations. 690 
Cell counts were assessed using CountBright™ Absolute Counting Beads (C36950, 691 
Thermo Fisher Scientific) on CD19+-gated populations. 692 
Apoptotic cell death was assessed by dual staining with Annexin V-Alexa Fluor 647 693 
(A23204, Thermo Fisher Scientific) and DAPI in CD19+-gated populations. Cells were 694 
washed in Annexin V binding buffer (556454, BD Biosciences) and stained with the B 695 
lineage ALL marker CD19-PE (clone 4G7; 345777, BD Biosciences) and Annexin V Alexa 696 
Fluor 647 for 15 min, protected from light. DAPI (1:2,000 in Annexin V binding buffer) was 697 
added prior to flow cytometric analysis. 698 
Cell cycle assessment was performed by Ki67 and DAPI dual staining on CD19+-gated 699 
populations. Cells were washed in DPBS containing 2% FBS and stained with CD19-PE 700 
and Fixable Viability Dye eFluor™ 780 (65-0865-14, Thermo Fisher Scientific) for 30 min at 701 
4°C. Cells were then fixed with ice-cold 70% ethanol and kept at -20°C. Subsequently, the 702 
samples were washed twice in DPBS containing 2% FBS, stained with Ki67-FITC (556026, 703 
BD Biosciences) for 30 min, and protected from light. DAPI (1:500 in DPBS containing 2% 704 
FBS) was added prior to flow cytometric analysis. Gating of the different phases of the cell 705 
cycle was determined by population analysis and isotype controls. 706 
Intracellular lipid content was assessed by BODIPY™ 493/503 staining. Cells were washed 707 
in DPBS and stained with BODIPY™ 493/503 (4,4-Difluoro-1,3,5,7,8-Pentamethyl-4-Bora-708 
3a,4a-Diaza-s-Indacene) (D3922, Thermo Fisher Scientific) for 30 min at 37°C. 709 
Subsequently, the samples were washed in DPBS, and DAPI (1:2,000 in DPBS) was added 710 
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prior to flow cytometric analysis. BODIPY median fluorescence intensity (MFI) was 711 
determined as a quantification of intracellular lipid content. 712 
For the assessment of the expression of the transmembrane fatty acid transporter CD36, 713 
cells were washed in DPBS containing 2% FBS and stained with CD36-APC (clone CB38; 714 
550956, BD Biosciences) together with CD19-PE and CD10-APC (clone HI10a 332777 BD 715 
Biosciences) for primary ALL samples or CD34-APC (clone; 555824 BD Biosciences) 716 
together with CD33-PE (clone WM53; 555450, BD Biosciences) for AML samples. Gating 717 
strategies for flow cytometry are summarised in Supplementary Fig. 6. 718 
 719 
 720 
Osmium staining 721 
Following euthanasia, murine tibiae were isolated, thoroughly cleaned and fixed in 10% 722 
formalin at 4°C for 48 h. Bones were decalcified for 14 days in 14% EDTA and washed in 723 
Sorensen’s phosphate buffer. Bones were then stained for 48 h in 1% osmium tetroxide 724 
(Agar Scientific), washed in Sorensen’s phosphate buffer and embedded in 1% agarose, 725 
forming layers of five tibiae arranged in parallel in a 30 ml universal tube. Tubes of 726 
embedded tibiae were then mounted in a Skyscan 1172 desktop micro CT (Bruker microCT, 727 
Kontich). Samples were scanned through 360° using a step of 0.40° between exposures. A 728 
voxel resolution of 12.05 μm was obtained in the scans using the following control settings: 729 
54 kV source voltage, 185 μA source current with an exposure time of 885 ms. A 0.5 mm 730 
aluminium filter and two-frame averaging were used to optimize the scan. After scanning, 731 
the data were reconstructed using NRecon v1.6.9.4 software (Bruker, Kontich, Belgium). 732 
The reconstruction thresholding window was optimized to encapsulate the target image. 733 
Volumetric analysis was performed using a CT Analyser v1.13.5.1 (Bruker microCT, 734 
Kontich). 735 
 736 
Xenotransplantation experiments 737 
All animal experiments were performed under license PPL 70/8540 approved by the Home 738 
Office of the United Kingdom and in accordance with institutional guidelines. 739 
Immunodeficient male (to avoid gender-based variation in adiposity) NSG mice (NOD. Cg-740 
Prkdcscid 112rgtm1Wjl/SzJ) were obtained from Charles Rivers Laboratories. All mice were 741 
housed in barrier accommodation in the Biological Services Unit at Queen Mary University 742 
of London, Charterhouse Square. Thawed MNCs obtained from PB or BM from ALL 743 
patients at diagnosis were resuspended in DPBS containing 10% FBS, and 5-8x106 cells 744 
were administered intravenously into the tail vein of 7- to 10-week-old nonirradiated mice. 745 
For Nalm-6 xenotransplantation, 0.5x106 cells were injected. Engraftment of human 746 
leukaemic cells was examined every two weeks by intratibial bone marrow sampling under 747 
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anaesthesia (isoflurane) and postprocedure analgesia (0.1 mg/kg vetergesic). Animal 748 
wellbeing and weight were regularly monitored, and mice were euthanized when signs of 749 
disease-related symptoms developed, in compliance with approved protocols or at 750 
leukaemia cell engraftment of >70%, as determined by intratibial sampling. This threshold 751 
was approximately reached 6-8 weeks after tumour inoculation of primary ALL and 3-4 752 
weeks with the Nalm-6 ALL cell line. At sacrifice, bone marrow cells from the femur and the 753 
tail vertebrae were isolated by mechanically crushing the bones with a mortar and pestle in 754 
DPBS containing 2% FBS, followed by filtration through a 40 µM nylon mesh to obtain a 755 
single-cell suspension. Following centrifugation, cell pellets were subjected to red blood cell 756 
lysis using ammonium chloride (07850, STEMCELL Technologies) prior to flow cytometric 757 
analysis. Gonadal fat tissue was microdissected at sacrifice, chopped and then digested 758 
with Liberase (5401119001, Roche) for 30 min at 37°C and processed as previously 759 
described 39. Flow cytometric assessment of primary human leukaemia engraftment was 760 
performed by CD19-PE and CD45-FITC (clone 2D1; 345808, BD Biosciences) co-staining 761 
of DAPI-viable cells or CD19-PE and CD10-FITC (clone W8E7; 347503, BD Biosciences) 762 
costaining in the case of Nalm-6 engraftment. Cell cycle analysis was performed on CD19+-763 
gated populations as described under “Flow cytometry”. For Op-Puro analysis, 0.5x106 cells 764 
from femoral or tail bone marrow were incubated with 10 µM OP-Puro reagent in RPMI 765 
medium containing 10% FBS for 20 min at 37°C. OP-Puro incorporation analysis was 766 
performed on CD19- and CD45+-gated populations as described under “O-propargyl-767 
puromycin (OPP) labelling”. 768 
 769 
Western blot analysis 770 
Total cellular protein content was extracted in NuPAGE™ LDS Sample Buffer (NP0007, 771 
Thermo Fisher Scientific) containing 50 mM dithiothreitol (NuPAGE™ Sample Reducing 772 
Agent; NP0009, Thermo Fisher Scientific). Protein content was quantified using the 773 
Pierce™ BCA Protein Assay Kit (23227, Thermo Fisher Scientific). Proteins were separated 774 
on NuPAGE™ 4-12% Bis-Tris polyacrylamide gels (NP0335BOX, Thermo Fisher Scientific) 775 
and transferred onto 0.45 µM PVDF transfer membranes (88518, Thermo Fisher Scientific). 776 
Membranes were blocked in Tris-buffered saline containing 0.1% TWEEN 20 and 5% BSA 777 
for 60 min at RT and then incubated with primary antibodies overnight at 4°C. HRP-778 
conjugated secondary antibodies were used at a 1:5,000 dilution (anti-rabbit 7074 and anti-779 
mouse 7076, Cell Signaling Technology). Protein signals were developed using 780 
SuperSignal™ West Pico PLUS Chemiluminescent Substrate (34577, Thermo Fisher 781 
Scientific), and images were acquired using an Amersham Imager 600 RGB (GE 782 
Healthcare). Densitometric analysis of immunoblots was performed using ImageJ software. 783 
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Primary antibodies were purchased from Cell Signaling Technology: P21 (12D1, 2947), P27 784 
(D69C12, 3686), phospho-P53 (Ser46, 2521), Cyclin D1 (E3P5S, 55506), Cyclin E (HE12, 785 
4129), phospho-Rb (Ser807/811, 8516), E2F-1 (3742), Phospho-AMPK (Thr172, 2531), 786 
Phospho-mTOR (Ser2448; 2971), Phospho-S6 Ribosomal Protein (Ser235/236; 2211), S6 787 
Ribosomal Protein (5G10; 2217), Phospho-4EBP1 (Thr37/46; 2855), 4EBP1 (53H11; 9644), 788 
Phospho-eIF2α (Ser51; 9721), eIF2α (9722) and ATF4 (D4B8; 11815). The anti α-Tubulin 789 
antibody was purchased from Abcam (DM1A; ab7291). All primary antibodies were diluted 790 
1:1,000. In specified experiments, ISRIB (200 nM, S7400, Selleckchem), PERK inhibitor (2 791 
µM; GSK2606414) or GCN2ib (5 µg/mL; HY-112654), 250 nM thapsigargin (1138, Tocris 792 
Bioscience) or 1 µM Torin 1 (4247, Tocris Bioscience) prior to cell harvest and lysate 793 




Two technical replicates of ALL cells (3x106) were harvested from 3T3-L1 adipocytes or 798 
preadipocytes as described under “ALL coculture experiments”. Cell pellets were washed 799 
twice in ice-cold DPBS, prepared by snap freezing on dry ice and submitted to MS-Omics 800 
for lipidomic profiling. Lipids were extracted from the samples using methanol, ultrapure 801 
water and methyl tert-butyl ether. The organic phase used for lipid analysis was separated, 802 
transferred to injection vials, dried under nitrogen flow and reconstituted in an 803 
isopropanol/acetontril/water mixture. For quality control, a mixed pooled sample (QC 804 
sample) was created by taking a small aliquot from each sample. This sample was analysed 805 
at regular intervals throughout the sequence. Matrix effects were tested for quantified 806 
compounds by spiking the QC sample at a minimum of two levels. Chromatographic 807 
separation was performed using a UPLC system (Vanquish, Thermo Fisher Scientific) 808 
coupled with a high-resolution quadrupole-orbitrap mass spectrometer (Q Exactive™ HF 809 
Hybrid Quadrupole-Orbitrap, Thermo Fisher Scientific). An electrospray ionization interface 810 
was used as the ionization source. Analysis was performed in negative and positive 811 
ionization modes. A QC sample was analysed in MS/MS mode for identification of 812 
compounds. UPLC was performed using a slightly modified version of the protocol 813 
described by Isaas et al. 61. Data were processed using Compound Discoverer 3.0 (Thermo 814 
Fisher Scientific). 815 
 816 
Oleic acid treatment 817 
ALL cells at a concentration of 0.2x106 cells in 1 ml RPMI medium (containing 10% FBS and 818 
antibiotics) were treated with 30 or 100 µM oleic acid-albumin from bovine serum (O3008, 819 
Merck KGaA) for 24, 48 or 72 h. Treatment with 0.3% bovine serum albumin (A7511, Merck 820 
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KGaA) was used as a control. An additional 1 ml of medium with the corresponding 821 
treatment was supplemented after 24 h. Cell counts and viability measurements were 822 
performed using acridine orange/propidium iodide staining. 823 
 824 
Fatty acid translocation experiments using BODIPY 825 
To examine directional lipid transfer from adipocytes to ALL cells, 3T3-L1 adipocytes were 826 
incubated with 2 µg/ml BODIPY™ 558/568 C12 (4,4-Difluoro-5-(2-Thienyl)-4-Bora-3a,4a-827 
Diaza-s-Indacene-3-Dodecanoic Acid) (D3835, Thermo Fisher Scientific) for 4 h. The 828 
adipocytes were washed with HBSS containing 0.2% fatty acid-free BSA to remove 829 
extracellular fatty acids. Subsequently, ALL cell lines at a concentration of 0.2x106 cells/ml 830 
were cocultured with labelled 3T3-L1 adipocytes for 24 h before being harvested, washed 831 
with HBSS containing 0.2% fatty acid-free BSA and analysed by an Amnis® 832 




Short hairpin RNA CD36 targeting 837 
Knockdown of CD36 was achieved using MISSION® shRNA lentiviral transduction particles 838 
cloned into the pLKO.1 lentiviral vector (CD36 shRNA: SHCLNV, nonmammalian shRNA 839 
control: SHC002V, Merck KGaA). Sequences of transduction particles are listed in 840 
Supplementary Table 4. Cells were plated in 6-well plates (0.25x106 cells/well) and treated 841 
with 5 µg/ml polybrene for 15 min prior to transduction with the appropriate lentiviral 842 
particles at a multiplicity of infection of 1. Cells were incubated with the particles for 72 h, 843 
and then selection with 1.0 µg/ml puromycin was performed until use in experiments. Cells 844 
were assayed for knockdown of CD36 by RT-qPCR. 845 
 846 
Quantitative real-time PCR 847 
RNA was extracted with a RNeasy Micro Kit (74004, Qiagen) following the manufacturer’s 848 
protocol. RNA was quantified (total RNA, 18S rRNA and 28S rRNA), and RNA integrity was 849 
assessed using an RNA ScreenTape (5067-5576, Agilent), RNA ScreenTape Sample 850 
Buffer (5067-5577, Agilent) and the 4200 TapeStation System (G2991AA, Agilent). RNA 851 
was reverse transcribed using the High-Capacity cDNA Reverse Transcription Kit (4368814, 852 
Thermo Fisher Scientific). Quantitative real-time PCR was performed on a Touch™ Real-853 
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Time thermal cycler (CFX384, Bio-Rad) using SsoAdvanced™ Universal SYBR® Green 854 
Supermix (1725271, Bio-Rad). Target primer sequences are listed in Supplementary Table 855 
5. β-Actin was used to normalize the RNA content. All samples were analysed in triplicate 856 
and averaged. 857 
 858 
Phosphoproteomic LC-MS/MS analysis 859 
Nalm-6 cells were cocultured with 3T3-L1 adipocytes or preadipocytes for 24 or 72 h in 150 860 
mm culture dishes (see ALL coculture experiments). Cells were isolated from coculture, and 861 
cell lysis and trypsin digestion were performed following previously described protocols in 862 
urea buffer (8 M urea in 20 mM in HEPES pH 8.0 supplemented with 1 mM Na3VO4, 1 mM 863 
NaF, 1 mM Na4P2O7 and 1 mM sodium β-glycerophosphate) 
40,62. Briefly, proteins were 864 
quantified by BCA assay, and 250 µg of protein was reduced and alkylated by sequential 865 
incubation with 10 mM dithiothreitol and 16.6 mM iodoacetamyde. Urea was diluted to a 866 
concentration of 1.44 M with 20 mM HEPES (pH 8.0), and samples were incubated with 867 
trypsin beads [50% slurry of TLCK-trypsin (20230, Thermo-Fisher Scientific)] on a 868 
thermoshaker overnight. Peptide solutions were then desalted using 10 mg OASIS-HLB 869 
cartridges (Waters, Manchester, UK) and eluted with glycolic acid buffer (1 M glycolic acid, 870 
50% ACN, 5% TFA). Phosphopeptides were enriched as previously described using 50 µL 871 
of TiO2 beads [(50% slurry in 1% TFA) GL Sciences] 
40,62. For phosphopeptide recovery, 872 
peptides were eluted in 5% NH4OH; dried peptide extracts were then dissolved in 0.1% TFA 873 
and analysed in an LC-MS/MS system. This consisted of a nanoflow ultra-high pressure 874 
liquid chromatography system nanoflow ultimate 3000 RSL nano (Dionex) coupled to a Q 875 
Exactive™ Plus Orbitrap™ Mass Spectrometer (Thermo Fisher Scientific). 876 
The LC system used mobile phases A (3% ACN: 0.1% FA) and B (100% ACN; 0.1% FA). 877 
Peptides were loaded onto a μ-precolumn (160454) and separated in an analytical column 878 
(EASY-Spray; ES803). The gradient was 1% B for 5 min and 1% B to 35% B for 60 min. 879 
Following elution, the column was washed with 85% B for 7 min and equilibrated with 3% B 880 
for 7 min at a flow rate of 0.25 µL/min. Peptides were nebulized into the online connected 881 
Q-Exactive Plus system operating with a 2.1 s duty cycle. Acquisition of full-scan survey 882 
spectra (m/z 375-1,500) with a 70,000 FWHM resolution was followed by data-dependent 883 
acquisition in which the 15 most intense ions were selected for HCD (higher energy 884 
collisional dissociation) and MS/MS scanning (200-2,000 m/z) with a resolution of 17,500 885 
FWHM. A 30 sec dynamic exclusion period was enabled with an exclusion list with a 10 886 
ppm mass window. The oxverall duty cycle generated chromatographic peaks of 887 
approximately 30 sec at the base, which allowed the construction of extracted ion 888 
chromatograms (XICs) with at least ten data points. 889 
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Peptide identification and quantification: Mascot Distiller 2.7.1 was used to fit an ideal 890 
isotopic distribution to the MS/MS data to maximize peptide identification, and the Mascot 891 
Daemon 2.6 search engine was used to match peaks to peptides in proteins present in the 892 
UniProt/SwissProt Database (human species). The process was automated with Mascot 893 
Daemon 2.5.0, mass tolerance was set to ± 10 ppm, and variable modifications phospho 894 
(ST), phospho (Y) glnpyro-glu (N-term Q) and oxidation (M) were included in the search. 895 
Carbamidomethyl (C) as fixed modification. Trypsin was selected as the digestion enzyme, 896 
and 2 missed cleavages were allowed. Sites of modification were reported when they had 897 
delta scores >10. Peptide and subsequent protein quantification was achieved using in-898 
house developed Peak statistics calculator (PESCAL) software 63. PESCAL constructs XICs 899 
for each peptide identified with the MASCOT search engine. With each constructed XIC, 900 
peak heights could be calculated. These peptide peak heights were then normalized to the 901 
sum of the intensities for each individual sample, and the average fold change between 902 
conditions could be determined. Statistical significance between conditions was considered 903 
significant when Student’s t tests produced a p-value<0.05 following correction with 904 
Benjamini Hochberg multiple testing. Further data processing and analysis were conducted 905 
within Microsoft Excel (2013) or R (v3.4.4 – reshape2, ggplot2, gplots, readxl, Hmisc and 906 
ggrepel packages). The Z-score was calculated based on the fold change, as previously 907 
described 40,64. 908 
 909 
KSEA and gene ontology analysis  910 
Kinase substrate enrichment analysis (KSEA) was performed as follows40; briefly, peptides 911 
differentially phosphorylated between a set of samples (at non-adjusted p-value<0.05) were 912 
grouped into substrate sets known to be phosphorylated by a specific kinase as annotated 913 
in the PhosphoSite, Phospho. ELM, and PhosphoPOINT databases 65-67. To infer 914 
enrichment of substrate groups across sets of samples, the hypergeometric test was used, 915 
followed by correction with Benjamini Hochberg multiple testing. For gene ontology 916 
analysis, proteins differentially phosphorylated between conditions (at non-adjusted p-917 
value<0.05) were grouped into gene ontologies (biological process) as annotated in UniProt 918 
databases. To infer ontology enrichment across sets of samples, the hypergeometric test 919 
was used, followed by correction with Benjamini Hochberg multiple testing. 920 
 921 
O-propargyl-puromycin (OPP) labelling 922 
The Click-iT™ Plus O-propargyl-puromycin (OPP) Alexa Fluor™ 647 Protein Synthesis 923 
Assay Kit (C10458, Thermo Fisher Scientific) was used to measure global protein 924 
synthesis. ALL cells were isolated from their microenvironment as described under “ALL 925 
coculture experiments” and immediately incubated with 10 µM OP-Puro for 20 min at 37°C 926 
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in ALL cell line-specific media, RPMI containing 10% FBS and antibiotics. In specific 927 
experiments, 10 μg/ml cycloheximide (CHX; C4859, Merck KGaA) was added 10 min prior 928 
to OP-Puro to block protein translation, thereby serving as a positive control. Cells were 929 
subsequently washed in DPBS containing 2% FBS and stained with CD19-PE. A further 930 
wash was performed prior to fixation with the Fixation/Permeabilization Solution Kit 931 
(554714, BD Biosciences). Incubation with the Click-iT® Plus OPP reaction cocktail 932 
provided in the kit containing Alexa Fluor® 647 picolyl azide for 30 min led to the "click" 933 
reaction and azide-alkyne cycloaddition. Additional DPBS containing 2% FBS washes 934 
followed prior to addition of DAPI (1:2,000 in DPBS containing 2% FBS) and flow cytometric 935 
analysis. OP-Puro MFI was measured to quantify protein synthesis. To assess the effect of 936 
proteasome activity on OP-Puro incorporation, cells were treated with 10 µM MG-132 937 
(M7449, Merck KGaA) for 2 h. At the final 20 min of incubation, 10 µM OP-Puro reagent 938 
was added. 939 
For the rescue experiment, ALL cells were cocultured with either 3T3-L1 adipocytes or 940 
preadipocytes for 24 h, and then 0.5x106 cells were extracted from their microenvironment, 941 
washed and recultured in fresh RPMI medium for an additional 48 h. ALL cells (0.5x106) 942 
were plated in parallel as a monoculture control. Cell number and OP-puro incorporation at 943 
24 and 48 h following microenvironmental extraction were assessed. 944 
 945 
In vitro Transwell experiments 946 
Transwell assays were performed as previously described 68. In brief, 0.5x106 Nalm-6 cells 947 
resuspended in 5 ml RPMI containing 10% FBS and antibiotics were added to the upper 948 
chamber, with confluent 3T3-L1 adipocytes or preadipocytes placed in the bottom chamber 949 
of a 24 mm Corning® Transwell system with 0.4 μm pore polyester membrane inserts 950 
(CLS3450, Corning NY Merck KGaA). After +24 h, the number of CD19+ Nalm-6 cells in the 951 
upper chamber and OP-puro incorporation in CD19+ Nalm-6 cells were quantified as 952 
described under “Flow cytometry” and “O-propargyl-puromycin (OPP) labelling”. 953 
 954 
Adipocyte secretome experiment 955 
3T3-L1 adipocytes and preadipocytes were cultured for 72 h in 100% confluent 100 mm cell 956 
culture dishes, and culture medium was collected and stored at -20°C until use. Nalm-6 cells 957 
were adapted to DMEM for 72 h prior to seeding at a concentration of 2x106 cells in 4 ml 958 
adipocyte- or preadipocyte-conditioned medium, following which cell number (using 959 
CountBright™ Absolute Counting Beads) and protein translation were assessed as 960 




Stress experiments 963 
Nalm-6 cells were isolated from monoculture or from 3T3-L1 adipocyte coculture at 48 h, 964 
washed twice in DPBS and resuspended in ALL cell line-specific media at equivalent 965 
densities of 105 cells/100 µl per well in black NuncTM F96 MicroWellTM plates (137101, 966 
Thermo Fisher Scientific). Subsequently, various treatments were added (final 967 
concentrations): 0.1 µg/ml cytarabine, 0.01 µg/ml vincristine, 0.1 µg/ml daunorubicin or a 968 
combination of the three chemotherapeutic agents with 100 µM hydrogen peroxide (H1009, 969 
Merck KGaA). Nutritional deprivation was induced by replating cells without the addition of 970 
FBS. In specified experiments, GCN2ib (5 µg/mL; HY-112654, Selleckchem) was added 971 
along with the indicated cellular stressor(s). At the indicated times, cell viability was 972 
assessed using the CellTiter-Glo® Luminescent Cell Viability Assay according to the 973 
manufacturers’ instructions. Luminescence was recorded using a FLUOstar Omega 974 
microplate reader. Luminescence signals were normalized to untreated controls at the 975 
respective timepoints. For confirmation, untreated controls were assessed at +4 h following 976 
microenvironmental extraction to confirm the persistence of translation arrest using O-977 




Pulsed SILAC-based proteomic analysis 982 
Nalm-6 cells were cocultured with 3T3-L1 adipocytes or preadipocytes for 24 or 48 h in 150 983 
mm culture dishes (see ALL coculture experiments). Subsequently, the cells were pulsed 984 
with either ‘heavily’ (H) or ‘moderately’ (M) isotope-labelled amino acids for +4 h. Cells were 985 
then isolated from coculture, lysed in 2% SDS and 50 mM Tris-HCl pH 7.5, sonicated and 986 
balanced following protein quantification. Equal amounts of the corresponding H&M lysates 987 
were then mixed together and subsequently trypsin digested using the filter-aided sample 988 
preparation (FASP) method69. Pooled peptides were then fractionated into seven peptide 989 
fractions using the Pierce™ High pH Reversed-Phase Peptide Fractionation Kit (84868, 990 
Thermo Fisher Scientific) according to the manufacturers’ instructions. Different fractions 991 
were then lyophilized and resuspended in 0.1% TFA and 2% acetonitrile prior to analysis on 992 
a Q Exactive™ Plus Orbitrap™ Mass Spectrometer coupled with a nanoflow ultimate 3000 993 
RSL nano HPLC platform (Thermo Fisher Scientific). Briefly, samples were resolved at a 994 
flow rate of 250 nl/min on an Easy-Spray 50 cm x 75 μm RSLC C18 column (Thermo Fisher 995 
Scientific) using a 123 min gradient of 3% to 35% of buffer B (0.1% formic acid in 996 
acetonitrile) against buffer A (0.1% formic acid in water), and the separated samples were 997 
infused into the mass spectrometer by electrospray. The spray voltage was set at 1.95 kV, 998 
and the capillary temperature was 255°C. The mass spectrometer was operated in data-999 
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dependent positive mode with 1 MS scan followed by 15 MS/MS scans (top 15 methods). 1000 
The scans were acquired in the mass analyser at 375-1500 m/z range, with a resolution of 1001 
70,000 for the MS scans and 17,500 for the MS/MS scans. Fragmented peaks were 1002 
dynamically excluded for 30 sec. MaxQuant (version 1.6.3.3) software was used for the 1003 
database search and SILAC quantification of mass spectrometry raw files 70. The search 1004 
was performed against a FASTA file of the human proteome extracted from UniProt.org. A 1005 
precursor mass tolerance of 4.5 ppm and a fragment mass tolerance of 20 ppm were 1006 
applied. Methionine oxidation and N-terminal acetylation were included as variable 1007 
modifications, while carbamidomethylation was applied as a fixed modification. Two trypsin 1008 
miscleavages were allowed, and the minimum peptide length was set to seven amino acids. 1009 
All other MaxQuant parameters apart from the ratio count cut-off (set at 1) were kept as 1010 
defaults. All raw files were searched together with the match between runs option set as 1011 
enabled and re-quantify option as disabled. All downstream data analyses were performed 1012 
with Perseus (version 1.5.5.3) 71 using the MaxQuant ProteinGroups.txt output file. Briefly, 1013 
protein H/M ratio values were converted to Log2 scale. Reverse (decoy) hits, potential 1014 
contaminants, and proteins identified only by modified peptides were filtered out. Proteins 1015 
were also filtered to have at least one valid H/M SILAC value. Fisher’s exact test was 1016 
performed with Perseus using a Benjamini-Hochberg FDR of 5%. 1017 
 1018 
 1019 
Statistical analysis 1020 
Data are presented as the mean with standard error of the mean or as the median with 1021 
interquartile ranges. Results with a p-value<0.05 were considered statistically significant. 1022 
Statistical analyses were performed using GraphPad Prism 8 software (GraphPad, San 1023 
Diego, CA). All data were subjected to normality testing prior to statistical assessment with 1024 
software-recommended tests. 1025 
 1026 
 1027 
Data availability statement 1028 
The datasets generated during the current study have been deposited to the Gene 1029 
Expression Omnibus repository via GEO accession number GSE151802 1030 
[https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE151802]. All raw mass spectrometry 1031 
files reported in this paper have been deposited to the ProteomeXchange Consortium via, 1032 
PXD019186 and PXD019369. All source data supporting the findings of this study are 1033 
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available within the article and its supplementary information files and from the 1034 
corresponding author upon reasonable request.  1035 
Code Availability 1036 
Custom pipelines for BM adipocyte analysis using Visiopharm software are available upon 1037 





We would like to thank staff from the Barts Cancer Institute tissue bank for samplecollection 1041 
and  processing. This work was supported by Blood Cancer UK (grant 15009; B Patel), The 1042 
Greg Wolf Foundation (B Patel) Cancer Research UK (grant CRUK A21019; B Patel, co-1043 
applicant), and Gabrielle’s Angels Foundation (B Patel). W.C. was supported by a grant from 1044 
the Medical Research Council (MR/M021394/1). This work was supported by a Cancer 1045 
Research UK Centre Grant C16420/A18066.  1046 
 1047 
Author Contributions 1048 
B. Patel, Q.H, C.X. and F.M.M. and designed the experiments. A. Clear developed the 1049 
Visiopharm analysis pipeline and performed digital histological analysis. Q.H. I.P., F.M.M., 1050 
C.X. and prepared patient samples and performed laboratory assays. M.C. reviewed the 1051 
histological analysis. P.C. performed the phosphoproteomic analysis. F.Z. performed the 1052 
SILAC analysis. W.C. supervised the osmium tetroxide analysis. K.S. performed osmium 1053 
tetroxide imaging and data analysis. Q.H., A.N., K.K., A.W. and B. Peck analysed the RNA 1054 
sequencing data. D.B. provided animals and facilities. L.M. performed animal experiments. 1055 
M.A. acquired and organized the data. B. Patel, D.T., J.G.G., M.S., H.O., J.D.C. and A. 1056 
Castleton provided clinical samples and data. B. Patel, C.X. and Q.H. interpreted the results. 1057 
B. Patel designed the study, wrote the manuscript and supervised the project. All authors 1058 
critically reviewed the manuscript and approved the final version. 1059 
 1060 
Competing interests 1061 




1. Hunger, S.P., et al. Improved survival for children and adolescents with acute lymphoblastic 1066 
leukemia between 1990 and 2005: a report from the children's oncology group. Journal of 1067 
38 
 
clinical oncology : official journal of the American Society of Clinical Oncology 30, 1663-1669 1068 
(2012). 1069 
2. Goldstone, A.H., et al. In adults with standard-risk acute lymphoblastic leukemia, the 1070 
greatest benefit is achieved from a matched sibling allogeneic transplantation in first 1071 
complete remission, and an autologous transplantation is less effective than conventional 1072 
consolidation/maintenance chemotherapy in all patients: final results of the International 1073 
ALL Trial (MRC UKALL XII/ECOG E2993). Blood 111, 1827-1833 (2008). 1074 
3. Patel, B., et al. Minimal residual disease is a significant predictor of treatment failure in non 1075 
T-lineage adult acute lymphoblastic leukaemia: final results of the international trial UKALL 1076 
XII/ECOG2993. Br J Haematol 148, 80-89 (2010). 1077 
4. Gokbuget, N., et al. Adult patients with acute lymphoblastic leukemia and molecular failure 1078 
display a poor prognosis and are candidates for stem cell transplantation and targeted 1079 
therapies. Blood 120, 1868-1876 (2012). 1080 
5. Bruggemann, M., et al. Clinical significance of minimal residual disease quantification in 1081 
adult patients with standard-risk acute lymphoblastic leukemia. Blood 107, 1116-1123 1082 
(2006). 1083 
6. Ebinger, S., et al. Characterization of Rare, Dormant, and Therapy-Resistant Cells in Acute 1084 
Lymphoblastic Leukemia. Cancer Cell 30, 849-862 (2016). 1085 
7. Lutz, C., et al. Quiescent leukaemic cells account for minimal residual disease in childhood 1086 
lymphoblastic leukaemia. Leukemia 27, 1204-1207 (2013). 1087 
8. Schroeder, M.P., et al. Integrated analysis of relapsed B-cell precursor Acute Lymphoblastic 1088 
Leukemia identifies subtype-specific cytokine and metabolic signatures. Scientific reports 9, 1089 
4188-4188 (2019). 1090 
9. Dobson, S.M., et al. Relapse-Fated Latent Diagnosis Subclones in Acute B Lineage Leukemia 1091 
Are Drug Tolerant and Possess Distinct Metabolic Programs. Cancer Discov (2020). 1092 
10. Meads, M.B., Gatenby, R.A. & Dalton, W.S. Environment-mediated drug resistance: a major 1093 
contributor to minimal residual disease. Nat Rev Cancer 9, 665-674 (2009). 1094 
11. Crane, G.M., Jeffery, E. & Morrison, S.J. Adult haematopoietic stem cell niches. Nat Rev 1095 
Immunol 17, 573-590 (2017). 1096 
12. Batsivari, A., et al. Dynamic responses of the haematopoietic stem cell niche to diverse 1097 
stresses. Nat Cell Biol 22, 7-17 (2020). 1098 
13. Zhang, B., et al. Altered microenvironmental regulation of leukemic and normal stem cells in 1099 
chronic myelogenous leukemia. Cancer Cell 21, 577-592 (2012). 1100 
14. Duan, C.W., et al. Leukemia propagating cells rebuild an evolving niche in response to 1101 
therapy. Cancer Cell 25, 778-793 (2014). 1102 
15. Colmone, A., et al. Leukemic cells create bone marrow niches that disrupt the behavior of 1103 
normal hematopoietic progenitor cells. Science 322, 1861-1865 (2008). 1104 
16. Hanoun, M., et al. Acute myelogenous leukemia-induced sympathetic neuropathy promotes 1105 
malignancy in an altered hematopoietic stem cell niche. Cell Stem Cell 15, 365-375 (2014). 1106 
17. Hawkins, E.D., et al. T-cell acute leukaemia exhibits dynamic interactions with bone marrow 1107 
microenvironments. Nature 538, 518-522 (2016). 1108 
18. Tikhonova, A.N., et al. The bone marrow microenvironment at single-cell resolution. Nature 1109 
569, 222-228 (2019). 1110 
19. Baryawno, N., et al. A Cellular Taxonomy of the Bone Marrow Stroma in Homeostasis and 1111 
Leukemia. Cell 177, 1915-1932.e1916 (2019). 1112 
20. Severe, N., et al. Stress-Induced Changes in Bone Marrow Stromal Cell Populations Revealed 1113 
through Single-Cell Protein Expression Mapping. Cell Stem Cell 25, 570-583.e577 (2019). 1114 
21. Marks, D.I., et al. T-cell acute lymphoblastic leukemia in adults: clinical features, 1115 
immunophenotype, cytogenetics, and outcome from the large randomized prospective trial 1116 
(UKALL XII/ECOG 2993). Blood 114, 5136-5145 (2009). 1117 
39 
 
22. Pitt, L.A., et al. CXCL12-Producing Vascular Endothelial Niches Control Acute T Cell Leukemia 1118 
Maintenance. Cancer Cell 27, 755-768 (2015). 1119 
23. Ehsanipour, E.A., et al. Adipocytes cause leukemia cell resistance to L-asparaginase via 1120 
release of glutamine. Cancer Res 73, 2998-3006 (2013). 1121 
24. Cahu, X., et al. Bone marrow sites differently imprint dormancy and chemoresistance to T-1122 
cell acute lymphoblastic leukemia. Blood Advances 1, 1760 (2017). 1123 
25. Behan, J.W., et al. Adipocytes impair leukemia treatment in mice. Cancer Res 69, 7867-7874 1124 
(2009). 1125 
26. Sheng, X., et al. Adipocytes Sequester and Metabolize the Chemotherapeutic Daunorubicin. 1126 
Mol Cancer Res 15, 1704-1713 (2017). 1127 
27. Sheng, X., et al. Adipocytes cause leukemia cell resistance to daunorubicin via oxidative 1128 
stress response. Oncotarget 7, 73147-73159 (2016). 1129 
28. Liu, H., et al. Consolidation Chemotherapy Prevents Relapse by Indirectly Regulating Bone 1130 
Marrow Adipogenesis in Patients with Acute Myeloid Leukemia. Cell Physiol Biochem 45, 1131 
2389-2400 (2018). 1132 
29. Masamoto, Y., et al. Adiponectin Enhances Quiescence Exit of Murine Hematopoietic Stem 1133 
Cells and Hematopoietic Recovery Through mTORC1 Potentiation. Stem Cells 35, 1835-1848 1134 
(2017). 1135 
30. Dominici, M., et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The 1136 
International Society for Cellular Therapy position statement. Cytotherapy 8, 315-317 (2006). 1137 
31. Boyd, A.L., et al. Acute myeloid leukaemia disrupts endogenous myelo-erythropoiesis by 1138 
compromising the adipocyte bone marrow niche. Nature cell biology 19, 1336-1347 (2017). 1139 
32. Corradi, G., et al. Mesenchymal stromal cells from myelodysplastic and acute myeloid 1140 
leukemia patients display in vitro reduced proliferative potential and similar capacity to 1141 
support leukemia cell survival. Stem Cell Res Ther 9, 271 (2018). 1142 
33. Azadniv, M., et al. Bone marrow mesenchymal stromal cells from acute myelogenous 1143 
leukemia patients demonstrate adipogenic differentiation propensity with implications for 1144 
leukemia cell support. Leukemia 34, 391-403 (2020). 1145 
34. Green, H. & Kehinde, O. An established preadipose cell line and its differentiation in culture. 1146 
II. Factors affecting the adipose conversion. Cell 5, 19-27 (1975). 1147 
35. Naveiras, O., et al. Bone-marrow adipocytes as negative regulators of the haematopoietic 1148 
microenvironment. Nature 460, 259-263 (2009). 1149 
36. Zhou, B.O., et al. Bone marrow adipocytes promote the regeneration of stem cells and 1150 
haematopoiesis by secreting SCF. Nat Cell Biol 19, 891-903 (2017). 1151 
37. Shafat, M.S., et al. Leukemic blasts program bone marrow adipocytes to generate a 1152 
protumoral microenvironment. Blood 129, 1320-1332 (2017). 1153 
38. Nieman, K.M., et al. Adipocytes promote ovarian cancer metastasis and provide energy for 1154 
rapid tumor growth. Nat Med 17, 1498-1503 (2011). 1155 
39. Ye, H., et al. Leukemic Stem Cells Evade Chemotherapy by Metabolic Adaptation to an 1156 
Adipose Tissue Niche. Cell Stem Cell 19, 23-37 (2016). 1157 
40. Casado, P., et al. Kinase-substrate enrichment analysis provides insights into the 1158 
heterogeneity of signaling pathway activation in leukemia cells. Sci Signal 6, rs6 (2013). 1159 
41. Zinngrebe, J., Debatin, K.M. & Fischer-Posovszky, P. Adipocytes in hematopoiesis and acute 1160 
leukemia: friends, enemies, or innocent bystanders? Leukemia 34, 2305-2316 (2020). 1161 
42. Ambrosi, T.H., et al. Adipocyte Accumulation in the Bone Marrow during Obesity and Aging 1162 
Impairs Stem Cell-Based Hematopoietic and Bone Regeneration. Cell Stem Cell 20, 771-1163 
784.e776 (2017). 1164 
43. Polymenis, M. & Aramayo, R. Translate to divide: small es, Cyrillicontrol of the cell cycle by 1165 
protein synthesis. Microb Cell 2, 94-104 (2015). 1166 
44. Wullschleger, S., Loewith, R. & Hall, M.N. TOR signaling in growth and metabolism. Cell 124, 1167 
471-484 (2006). 1168 
40 
 
45. Holcik, M. & Sonenberg, N. Translational control in stress and apoptosis. Nat Rev Mol Cell 1169 
Biol 6, 318-327 (2005). 1170 
46. Goncalves, K.A., et al. Angiogenin Promotes Hematopoietic Regeneration by Dichotomously 1171 
Regulating Quiescence of Stem and Progenitor Cells. Cell 166, 894-906 (2016). 1172 
47. Signer, R.A., Magee, J.A., Salic, A. & Morrison, S.J. Haematopoietic stem cells require a highly 1173 
regulated protein synthesis rate. Nature 509, 49-54 (2014). 1174 
48. Cahu, X., et al. Bone marrow sites differently imprint dormancy and chemoresistance to T-1175 
cell acute lymphoblastic leukemia. Blood Adv 1, 1760-1772 (2017). 1176 
49. Dhimolea, E., et al. An Embryonic Diapause-like Adaptation with Suppressed Myc Activity 1177 
Enables Tumor Treatment Persistence. Cancer cell 39, 240-256.e211 (2021). 1178 
50. Taylor, R.C. & Dillin, A. Aging as an event of proteostasis collapse. Cold Spring Harbor 1179 
perspectives in biology 3, a004440 (2011). 1180 
51. Rzonca, S.O., Suva, L.J., Gaddy, D., Montague, D.C. & Lecka-Czernik, B. Bone is a target for 1181 
the antidiabetic compound rosiglitazone. Endocrinology 145, 401-406 (2004). 1182 
52. Patel, J.J., Butters, O.R. & Arnett, T.R. PPAR agonists stimulate adipogenesis at the expense 1183 
of osteoblast differentiation while inhibiting osteoclast formation and activity. Cell Biochem 1184 
Funct 32, 368-377 (2014). 1185 
53. Park, J., Morley, T.S., Kim, M., Clegg, D.J. & Scherer, P.E. Obesity and cancer--mechanisms 1186 
underlying tumour progression and recurrence. Nat Rev Endocrinol 10, 455-465 (2014). 1187 
54. Fujimoto, J., et al. Identification of Novel, Potent, and Orally Available GCN2 Inhibitors with 1188 
Type I Half Binding Mode. ACS Med Chem Lett 10, 1498-1503 (2019). 1189 
55. Choi, J., Cha, Y.J. & Koo, J.S. Adipocyte biology in breast cancer: From silent bystander to 1190 
active facilitator. Prog Lipid Res 69, 11-20 (2018). 1191 
56. Kolonin, M.G. & DiGiovanni, J. The role of adipose stroma in prostate cancer aggressiveness. 1192 
Transl Androl Urol 8, S348-s350 (2019). 1193 
57. Wei, L., et al. Small bone marrow adipocytes predict poor prognosis in acute myeloid 1194 
leukemia. Haematologica 103, e21-e24 (2018). 1195 
58. Castro-Malaspina, H., et al. Characterization of human bone marrow fibroblast colony-1196 
forming cells (CFU-F) and their progeny. Blood 56, 289-301 (1980). 1197 
59. Nawaratne, R., et al. Regulation of insulin receptor substrate 1 pleckstrin homology domain 1198 
by protein kinase C: role of serine 24 phosphorylation. Molecular endocrinology (Baltimore, 1199 
Md.) 20, 1838-1852 (2006). 1200 
60. Cawthorn, W.P., Heyd, F., Hegyi, K. & Sethi, J.K. Tumour necrosis factor-alpha inhibits 1201 
adipogenesis via a beta-catenin/TCF4(TCF7L2)-dependent pathway. Cell Death Differ 14, 1202 
1361-1373 (2007). 1203 
61. Giorgis Isaac, S.M., and Giuseppe Astarita. Lipid Separation: UPLC System for the Separation 1204 
of Complex Biological Total Lipid Extracts.  (Water Application note 2011). 1205 
62. Wilkes, E.H., Terfve, C., Gribben, J.G., Saez-Rodriguez, J. & Cutillas, P.R. Empirical inference 1206 
of circuitry and plasticity in a kinase signaling network. Proc Natl Acad Sci U S A 112, 7719-1207 
7724 (2015). 1208 
63. Cutillas, P.R. Targeted In-Depth Quantification of Signaling Using Label-Free Mass 1209 
Spectrometry. Methods Enzymol 585, 245-268 (2017). 1210 
64. Kim, S.Y. & Volsky, D.J. PAGE: parametric analysis of gene set enrichment. BMC 1211 
Bioinformatics 6, 144 (2005). 1212 
65. Hornbeck, P.V., et al. PhosphoSitePlus, 2014: mutations, PTMs and recalibrations. Nucleic 1213 
Acids Res 43, D512-520 (2015). 1214 
66. Dinkel, H., et al. Phospho.ELM: a database of phosphorylation sites--update 2011. Nucleic 1215 
Acids Res 39, D261-267 (2011). 1216 
67. Yang, C.Y., et al. PhosphoPOINT: a comprehensive human kinase interactome and phospho-1217 
protein database. Bioinformatics 24, i14-20 (2008). 1218 
41 
 
68. Patel, B., et al. Mouse xenograft modeling of human adult acute lymphoblastic leukemia 1219 
provides mechanistic insights into adult LIC biology. Blood 124, 96-105 (2014). 1220 
69. Mardakheh, F.K., et al. Global Analysis of mRNA, Translation, and Protein Localization: Local 1221 
Translation Is a Key Regulator of Cell Protrusions. Dev Cell 35, 344-357 (2015). 1222 
70. Tyanova, S., Temu, T. & Cox, J. The MaxQuant computational platform for mass 1223 
spectrometry-based shotgun proteomics. Nat Protoc 11, 2301-2319 (2016). 1224 
71. Tyanova, S., Temu, T. & Sinitcyn, P. The Perseus computational platform for comprehensive 1225 
analysis of (prote)omics data. 13, 731-740 (2016). 1226 
 1227 
  1228 
42 
 
Figure Legends 1229 
Fig. 1: The adipocyte BM niche is dynamically remodelled during ALL pathogenesis 1230 
and treatment. a H&E-stained human BM biopsies from healthy control, patient with ALL at 1231 
diagnosis (ALL01 Diagnostic) and post remission induction treatment (ALL01 Remission 1232 
Induction). Representative of five independent healthy BM biopsies and eight independent 1233 
matched pairs of ALL diagnosis and remission biopsies analysed once/biopsy. Zoomed-in 1234 
images of the boxed regions are presented below. Black arrowheads indicate BM 1235 
adipocytes. Custom image analysis using Visiopharm software identifies individual BM 1236 
adipocytes as green objects. b Adipocyte numbers quantified by Visiopharm analysis in 1237 
healthy controls (n=5) and paired ALL diagnosis vs ALL remission BM biopsies (n=8). Each 1238 
datapoint denotes an independent biopsy. Data are normalized to the size of the biopsy. 1239 
**p<0.01 by one-way ANOVA with Tukey’s multiple comparison test. c Adipocyte size 1240 
quantified by Visiopharm analysis in healthy control (n= 5) and ALL diagnosis  (n=8, ALL01-1241 
ALL08) BM biopsies. Datapoints denote values for individual adipocytes (>45). The mean ± 1242 
SEM are shown. Statistical significance was assessed by a Kruskal-Wallis test with Dunn's 1243 
multiple comparisons test (****p<0.0001). d Adipocyte size quantified by Visiopharm analysis 1244 
in healthy control (n= 5) and ALL remission (rALL) BM biopsies (n=8). Datapoints denote 1245 
values for individual adipocytes (>72). The mean ± SEM are shown. Statistical significance 1246 
was assessed by a Kruskal-Wallis test with Dunn's multiple comparisons test (****p<0.0001). 1247 
e Adiponectin concentrations in serum samples from healthy control vs ALL diagnosis 1248 
(including ALL04, ALL17 and ALL21) BM. Adiponectin was quantified using a commercial 1249 
ELISA kit. Each datapoint denotes an independent BM serum sample. ***p<0.0006 by a 2-1250 
sided unpaired t test. f Morphological evaluation of residual ALL disease in H&E-stained BM 1251 
biopsies from four consecutively assessed patients with an incomplete response (< 5% 1252 
blasts) to remission induction chemotherapy. Individual images show ALL tumour-specific 1253 
immunostaining. Red arrows indicate ALL blasts in close proximity to BM adipocytes while 1254 
black arrows denote interstitially distributed ALL disease as assigned by 2 independent 1255 
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reviews .The percentage of residual ALL disease was obtained from clinical reports and is 1256 
indicated in red text. 1257 
 1258 
Figure 2. ALL corrupts the functioning and lineage priming of the adipocyte precursor 1259 
mesenchymal stromal cell (MSC) population. a Growth outcomes of ALL-MSCs (ALL12-1260 
ALL23) at P1. Each datapoint denotes an independent BM. ALL-MSCs were divided into 1261 
high and low performers defined by the group mean. Horizontal line denotes the median 1262 
*p<0.0132, ***p<0.001. b CFU-F numbers from seven independent ALL (ALL15-17, ALL19-1263 
21 and ALL23) and healthy-BMs after +10 days under MSC differentiation conditions. c 1264 
Adipocyte-specific FABP4 staining in ALL vs healthy-MSCs (left) and FABP4 fluorescence 1265 
quantification (right). Images are representative of seven and six independent BM samples, 1266 
respectively analysing 100 cells/sample. d Osteocalcin staining in ALL vs healthy-MSCs 1267 
(left) and osteocalcin fluorescence quantification (right). Images are representative of six and 1268 
five independent BM samples, respectively. For c and d comparisons are between each 1269 
individual ALL-MSC and the aggregated mean of healthy-MSCs. Horizontal line denotes the 1270 
median; boxes extend from the 25th to the 75th percentile e Representative micrographs (left) 1271 
showing intracellular lipid staining with oil red (magnification, 10x; scale bar, 200µm) 1272 
following in vitro adipogenic differentiation in the absence or presence of conditioned media 1273 
(CM) from cultured GMPB, from n= 3 biologically independent samples or from ALL cell lines 1274 
(Nalm-6, REH and RS4;11). Oil red staining was quantified in three independently assayed 1275 
wells/condition from one experiment. **p= 0.002, ***p=0.0004. f Principal component 1276 
analysis of global RNA-seq data from ALL-MSCs (ALL12-14) and age-matched healthy-1277 
MSCs (n=3). Each dot represents an individual BM-MSC. g GSEA comparing RNA-seq-1278 
generated global transcriptomes of ALL-MSCs (n=3) vs healthy-MSCs (n=3) by KEGG 1279 
pathway annotation. Significance was assigned by FDR q-value<0.05. Bars in green 1280 
correspond to downregulated pathways. h Gene set enrichment plot for the KEGG cell cycle 1281 
pathway demonstrating significant downregulation of these gene sets in ALL-MSCs (left). 1282 
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Ki67 cell cycle analysis of ALL-MSCs (n=4) vs healthy-MSCs (n=4) (right). Statistical 1283 
comparisons are between each cell cycle stage.  NES, normalized enrichment score; FDR 1284 
false discovery rate. *p= 0.029. Unless otherwise stated, all data are presented as mean 1285 
values ± SEM values of independent experiments (n =4 in a, n=3 in b, n= 1 in e and n=3 in 1286 
h.  Statistical significance was assessed using Kruskal-Wallis test with Dunn's multiple 1287 
comparisons test (a,b, c. d) 2-sided unpaired t tests (e,), two-sided Mann-Whitney U test (h). 1288 




Figure 3. Adipocytes create a tumour-suppressive niche in B-ALL. a Schematic of the 1293 
experimental setup to assess functional interactions between ALL and adipocyte niches. b In 1294 
vitro growth of ALL cell lines (Nalm-6, REH and RS4;11) in adipocyte and unrelated stromal 1295 
environments over time. Primary BM-MSCs from three independent healthy donors were 1296 
evaluated alongside their corresponding osteoblast and adipocyte derivative. c Frequency of 1297 
quiescent (G0) and cycling (G1 and S/G2/M) populations in ALL cells after monoculture (-) 1298 
vs adipocyte co-culture (+) from experiments described in b. Bottom panel shows 1299 
representative Ki67/DAPI staining in CD19+-gated Nalm-6 cells at +72 h. Percentage of cells 1300 
in each phase of the cell cycle is shown in red. d Schematic showing the different 1301 
microenvironments assayed for human ALL xenotransplantation studies. BM from the tail 1302 
and gonadal fat are designated adipocyte-rich niches, whereas femoral BM is adipocyte 1303 
poor. Arrows point to individual adipocytes. e Osmium-stained and micro-CT-imaged BM 1304 
adipocytes in whole femurs from NSG mice at +10 days. BM adipocyte production was 1305 
stimulated by sublethal (2.5 Gy) total body irradiation and served as a positive control. f and  1306 
g Engraftment outcomes of Nalm-6 (CD19+/CD10+) and four independent primary B-ALL 1307 
(CD19+/CD45+) tumours following tail vein IV injection in distinct in vivo niches. Statistical 1308 
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comparisons are with femur. h and i Comparison of cell cycle characteristics in Nalm-6 and 1309 
primary B-ALL xenografts respectively from experiments described in f and g. Not tested 1310 
indicates failure to perform robust cell cycle analysis due to low cell recovery. The panel on 1311 
the right shows representative Ki67/DAPI staining in CD19+ gated primary B-ALL xenografts 1312 
in the indicated niches. The percentage of cells in the G0 phase is shown in red. Data are 1313 
presented as mean values ± SEM values of independent experiments (n = 3 with 2-3 1314 
replicates in b, n = 1 in f,h with n=3 mice and n = 3 in g,i n =4-5 mice. Statistical significance 1315 
was assessed using 2-sided unpaired t tests (b, c, g:- ALL15 vs 23). ANOVA with Dunnett's 1316 
multiple comparisons test (f, g, i:- ALL24  vs ALL25), two-sided Mann-Whitney U-tests (h) 1317 
(*p<0.05, **p<0.01, ***p<0.001, ***p<0.001).  $$p<0.01, $$$p<0.001 for primary vs 3T3-L1 1318 
adipocytes. Only statistically significant comparisons are indicated (b,c). 1319 
 1320 
Figure 4. Adipocyte niches restrict protein synthesis in ALL via non-canonical factors. 1321 
a Venn diagram of significant phosphosites identified in Nalm-6 cells cultured with 3T3-L1 1322 
adipocytes at +24 (green) and +72 h (red). Bracketed values denote the corresponding 1323 
number of proteins. b Pathway analysis of the altered phosphoproteins from a. Z-score, red: 1324 
≤-1.5, pathway underrepresented; green: ≥+1.5, pathway overrepresented. GO terms are 1325 
grouped into categories that were hand curated. c Differential transcription level (log2) 1326 
between Nalm-6 cells cultured with 3T3-L1 adipocytes vs 3T3-L1 preadipocytes at +24 h. 1327 
Differentially transcribed genes (FDR q-value<0.05) are highlighted in red for each indicated 1328 
log2 FC range. Dashed red lines represent log2 FC thresholds -1 and 1.  Data derived from 1329 
RNAseq of three replicates/condition. d. GSEA comparing RNAseq-generated global 1330 
transcriptomes of 3T3-L1 adipocyte vs 3T3-L1 preadipocyte cultured Nalm-6 cells by KEGG 1331 
pathway annotation. Significant pathways defined by FDR q-value <0.05. (Red bar: 1332 
upregulated pathways, Green bar: downregulated pathways). e OP-Puro incorporation by 1333 
Nalm-6 cells under 3T3-L1 preadipocyte (grey) or 3T3-L1 adipocytes (blue) coculture relative 1334 
to monoculture. Nalm-6 monocultures treated with CHX, 10 µg/mL for 10 min (black), served 1335 
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as a positive control. Representative histograms of OP-Puro fluorescence are shown on the 1336 
right. f OP-Puro incorporation in vitro in Nalm-6 cells in G0/G1 vs S/G2/M fractions +72 hrs 1337 
after coculture with 3T3-L1 preadipocytes (grey) or 3T3-L1 adipocytes (blue). Data are 1338 
normalised to monocultures. g OP-Puro incorporation in CD19+/CD45+ xenografted primary 1339 
B-ALL cells (ALL24 and ALL25) harvested from femoral (blue) and tail (red) BMs according 1340 
to cell cycle stage. ALL24 G0/G1 p=0.0002, S/G2/M p=0.0003; ALL25 G0/G1 p=0.017, 1341 
S/G2/M p= 0.045.h Western blot showing p-eIF2α levels in Nalm-6 cells (5x106/) after 72 hrs 1342 
treatment with ISRIB, PERKi, or GCN2ib or Thapsigargin (250 nM), the latter serves as a 1343 
positive control. (representative of two independent experiments).i. OP-Puro incorporation in 1344 
Nalm-6 cells cocultured with 3T3-L1 adipocytes after 72h of GCN2ib  (5ug/mL) vs vehicle 1345 
treatment. The results are expressed relative to the OP-Puro fluorescence of Nalm-6 in 3T3-1346 
L1 pre-adipocyte co-culture. **p=0.0022.  j Frequency of G0 cells in Nalm-6 cells cocultured 1347 
with 3T3-L1 adipocytes after 72h of GCN2ib  (5ug/mL) vs vehicle treatment. **p=0.0017. 1348 
Data are presented as mean values ± SEM values of independent experiments (n=2 in c, n= 1349 
3 in e,f  assessing triplicates, n = 2 in g with n = 4 mice, n=2 in i,j  assessing triplicates. 1350 
Statistical significance was assessed using 2-sided unpaired t tests (e,g, i,j) **p<0.01. 1351 
***p<0.001, ****p<0.0001 or the precise p-value where indicated. 1352 
Figure 5. Adipocyte-adapted ALL proteomes increase global stress resistance.  a Cell 1353 
viability of Nalm-6 cells retrieved from monoculture (black, n=8)  vs 3T3-L1 adipocyte 1354 
coculture (blue, n=8) in the presence of the indicated chemotherapeutic agents or mitosis-1355 
independent stressors (no FBS and hydrogen peroxide). Data are presented relative to 1356 
vehicle controls. b. Cell viability of Nalm-6 cells after +48 h recovery from 3T3-L1 adipocyte 1357 
coculture (blue, n=4) or from monoculture (black, n=4) after exposure to mitosis-dependant 1358 
chemotherapy or mitosis-independent stressors (no FBS and hydrogen peroxide). Data are 1359 
presented relative to vehicle controls.  c. Cell viability of Nalm-6 monocultured (black, n=3) 1360 
or 3T3-L1 adipocyte-cocultured Nalm-6 cells (blue, n=3) in the presence of GCN2ib 1361 
treatment (5 µg/mL) and the indicated cellular stressors. d Schematic for pulsed SILAC-1362 
47 
 
based proteomic analysis. Nalm-6 cells cocultured with either 3T3-L1 adipocytes or 1363 
preadipocytes were pulsed at +24 h and at 48 h with either ‘heavy’ or ‘moderately’ isotope-1364 
labelled amino acids. Following a 4 h incubation, Nalm-6 cells were separated from their 1365 
microenvironment for protein extraction. Lysates were mixed in equal amounts (between 1366 
heavily and medium labelled samples at each time point), digested, fractionated and 1367 
analysed using mass spectrometry.e Scatter plot showing the normalized log2 ratio of 1368 
proteins detected following pulsed SILAC-based proteomic analysis in Nalm-6 cells 1369 
cocultured with 3T3-L1 adipocytes (Adipo) relative to preadipocytes (preadipo) at +24 h vs 1370 
48 h from one experiment. Blue Arrows describe the direction of change in adipocyte-1371 
specific coculture. Data are presented as mean values ± SEM values of independent 1372 
experiments (n=2 in a with four replicates, n = 1 with four replicates in b,c. Statistical 1373 
significance was assessed using 2-sided unpaired t tests (a,b for the single-agent 1374 
treatments) , Mann-Whitney U test for combination chemotherapy treatment (b) One-way 1375 
ANOVA followed by Tukey's test for multiple comparisons c. **p<0.01, ***p<0.001, 1376 
****p<0.0001. 1377 
Figure 6. a Graphical abstract showing the temporal course of adipocyte niches across the 1378 
ALL disease-remission transition and its pathophysiological relevance based on the 1379 
demonstration of adipocyte-driven modulations in ALL cell phenotype. 1380 
  1381 
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Table Legends 1382 
Table 1. Pathway analysis of the co-downregulated proteins (n= 413) at +24 and +48 h in 1383 
Nalm-6 cells cocultured with 3T3-L1 adipocytes, as detected by pulsed SILAC. Pathway 1384 
enrichment was assessed by two-sided Fisher’s exact tests with a Benjamini-Hochberg FDR 1385 
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KEGG_Drug metabolism other enzymes
KEGG_Antigen processing and presentation
KEGG_Pentose phosphate pathway
KEGG_Propanoate metabolism
KEGG_Citrate cycle TCA cycle
KEGG_Pathogenic Escherichia coli infection
KEGG_Glycolysis gluconeogenesis
KEGG_Fructose and mannose metabolsim
KEGG_RNA degradation
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GO terms - Biological Processes +24h +72h
Metabolism
ATP biosynthetic process
ATP hydrolysis coupled proton transport
Biotin metabolic process




Mitochondrial ATP synthesis coupled proton transport
Oxaloacetate metabolic process
Pyruvate metabolic process
Regulation of acetyl-CoA biosynthetic process from pyruvate
Respiratory electron transport chain







Cellular protein metabolic process
Chaperone-mediated protein complex assembly
ER-associated ubiquitin-dependent protein catabolic process
Protein folding





mRNA splicing, via spliceosome
Nuclear -transcribed mRNA catabolic process





Negative regulation of apoptotic process
Regulation of apoptotic process
Miscelleneous B cell activation
-5 0 + 5
G1/S transition of mitotic cell cycle
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Positive regulation of WNT signalling pathway
Protein refolding
RNA splicing




Chaperone mediated protein folding
Cellular amino acid metabolic process
Protein folding









































































































































































































































































































































































































24h 48h 24h & 48h



































Label with Heavy or Medium isotopic amino acids for 4h
Collect Nalm -6 cells, 
Mix 1:1 heavy and medium labelled lysates
















ALL Progression ALL Persistence
Low Proteome Flux
Global Stress Resistance 
QuiescenceHigh Expansion Rate
GCN2ib
Table 1. Pathway enrichment analysis of downregulated proteins in Nalm-6 cells co-cultured 











1 Keywords Elongation factor 3.1071 0.00034546 0.01708 
2 GOCC chaperonin-containing T-complex 3.1071 0.0001099 0.003187 
3 Keywords rRNA-binding 2.7618 0.00067496 0.026323 
4 GOCC cytosolic small ribosomal subunit 2.3052 1.25E-06 6.84E-05 
5 GOCC small ribosomal subunit 2.2597 1.31E-06 6.84E-05 
6 GOBP positive regulation of translation 2.244 0.00044973 0.036325 
7 GOBP 
regulation of cysteine-type 
endopeptidase activity 
2.1749 0.00044019 0.036147 
8 KEGG Ribosome 2.1128 4.68E-11 1.04E-08 
9 GOBP 
nuclear-transcribed mRNA catabolic 
process, nonsense-mediated decay 
2.0963 7.60E-12 7.49E-09 
10 GOBP 
nuclear-transcribed mRNA catabolic 
process 
2.0714 1.11E-12 2.73E-09 
11 GOBP mRNA catabolic process 2.0605 1.02E-12 2.73E-09 
12 Keywords Citrullination 2.0315 0.00035833 0.01708 
13 GOCC cytosolic large ribosomal subunit 2.0232 5.17E-06 0.00018405 
14 GOCC cell cortex part 2.0196 0.0019023 0.045137 
15 GOBP RNA catabolic process 2.0196 1.73E-12 2.83E-09 
 
 
